
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-Q

(Mark One)

- ☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the quarterly period ended **June 30, 2026**
OR
☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**
For the transition period from _____ to _____
Commission file number **001-33892**
-

AMC ENTERTAINMENT HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)
One AMC Way
11500 Ash Street, Leawood, KS
(Address of principal executive offices)

26-0303916
(I.R.S. Employer
Identification No.)

66211
(Zip Code)

Registrant's telephone number, including area code: **(913) 213-2000**

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Class A common stock	AMC	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulations S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐
Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standard provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Title of each class of common stock	Number of shares outstanding as of July 22, 2026
Class A common stock	892,604,638

AMC ENTERTAINMENT HOLDINGS, INC.

INDEX

	Page Number
<u>PART I—FINANCIAL INFORMATION</u>	
<u>Item 1. Financial Statements (Unaudited)</u>	3
<u>Condensed Consolidated Statements of Operations</u>	3
<u>Condensed Consolidated Statements of Comprehensive Income (Loss)</u>	4
<u>Condensed Consolidated Balance Sheets</u>	5
<u>Condensed Consolidated Statements of Cash Flows</u>	6
<u>Notes to Condensed Consolidated Financial Statements</u>	8
<u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	31
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	64
<u>Item 4. Controls and Procedures</u>	65
<u>PART II—OTHER INFORMATION</u>	
<u>Item 1. Legal Proceedings</u>	65
<u>Item 1A. Risk Factors</u>	66
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	69
<u>Item 3. Defaults Upon Senior Securities</u>	69
<u>Item 4. Mine Safety Disclosures</u>	70
<u>Item 5. Other Information</u>	70
<u>Item 6. Exhibits</u>	71
<u>Signature</u>	72

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements. (Unaudited)

AMC ENTERTAINMENT HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In millions, except share and per share amounts)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	(unaudited)		(unaudited)	
Revenues				
Admissions	\$ 863.1	\$ 762.6	\$ 1,441.5	\$ 1,236.1
Food and beverage	576.1	499.6	923.4	783.0
Other theatre	157.5	135.7	277.2	241.3
Total revenues	1,596.7	1,397.9	2,642.1	2,260.4
Operating costs and expenses				
Film exhibition costs	440.3	392.1	695.9	596.9
Food and beverage costs	107.7	96.1	174.1	153.3
Operating expense, excluding depreciation and amortization below	458.4	458.4	865.7	851.6
Rent	223.8	222.6	447.9	440.7
General and administrative:				
Merger, acquisition and other costs	0.3	0.1	1.4	3.1
Other, excluding depreciation and amortization below	52.0	58.2	112.9	114.2
Depreciation and amortization	76.1	77.8	151.8	153.9
Operating costs and expenses	1,358.6	1,305.3	2,449.7	2,313.7
Operating income (loss)	238.1	92.6	192.4	(53.3)
Other expense, net:				
Other expense (income)	109.6	(32.1)	57.2	(90.9)
Interest expense:				
Corporate borrowings	115.9	109.6	235.8	218.6
Finance lease obligations	1.7	1.4	3.2	2.6
Non-cash NCM exhibitor services agreement	18.4	18.6	36.9	27.5
Investment expense (income)	0.5	(1.4)	(17.8)	(7.1)
Total other expense, net	246.1	96.1	315.3	150.7
Loss before income taxes	(8.0)	(3.5)	(122.9)	(204.0)
Income tax provision	3.4	1.2	5.6	2.8
Net loss	\$ (11.4)	\$ (4.7)	\$ (128.5)	\$ (206.8)
Net loss per share:				
Basic and diluted	\$ (0.02)	\$ (0.01)	\$ (0.20)	\$ (0.48)
Weighted average shares outstanding:				
Basic and diluted (in thousands)	722,015	433,144	631,343	432,064

See Notes to Condensed Consolidated Financial Statements.

AMC ENTERTAINMENT HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
	(unaudited)		(unaudited)	
Net loss	\$ (11.4)	\$ (4.7)	\$ (128.5)	\$ (206.8)
Other comprehensive income (loss):				
Unrealized foreign currency translation adjustments	(16.2)	11.0	(31.7)	63.7
Net pension gain during the period	0.2	0.1	0.2	0.1
Other comprehensive income (loss)	(16.0)	11.1	(31.5)	63.8
Total comprehensive income (loss)	<u>\$ (27.4)</u>	<u>\$ 6.4</u>	<u>\$ (160.0)</u>	<u>\$ (143.0)</u>

See Notes to Condensed Consolidated Financial Statements.

AMC ENTERTAINMENT HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

(In millions, except share data)	June 30, 2026	December 31, 2025
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 778.4	\$ 428.5
Restricted cash	41.1	48.8
Receivables, net	125.6	156.0
Other current assets	93.1	97.2
Total current assets	1,038.2	730.5
Property, net	1,315.3	1,374.2
Operating lease right-of-use assets, net	2,964.2	3,137.3
Intangible assets, net	146.0	147.4
Goodwill	2,377.6	2,416.1
Other long-term assets	202.3	212.3
Total assets	<u>\$ 8,043.6</u>	<u>\$ 8,017.8</u>
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current liabilities:		
Accounts payable	\$ 396.7	\$ 382.9
Accrued expenses and other liabilities	332.1	338.2
Deferred revenues and income	452.6	465.5
Current maturities of corporate borrowings	148.9	19.9
Current maturities of finance lease liabilities	7.4	5.8
Current maturities of operating lease liabilities	560.4	560.0
Total current liabilities	1,898.1	1,772.3
Corporate borrowings	3,702.7	4,018.6
Finance lease liabilities	45.2	46.7
Operating lease liabilities	3,250.6	3,485.0
Exhibitor services agreement	455.9	459.1
Deferred tax liability, net	36.1	35.7
Other long-term liabilities	107.7	95.2
Total liabilities	9,496.3	9,912.6
Commitments and contingencies		
Stockholders' deficit:		
AMC Entertainment Holdings, Inc.'s stockholders' deficit:		
Preferred stock, \$.01 par value per share, 50,000,000 shares authorized; no shares issued and outstanding as of June 30, 2026, and December 31, 2025	—	—
Class A common stock (\$.01 par value, 1,100,000,000 shares authorized; 892,604,638 shares issued and outstanding as of June 30, 2026; 1,100,000,000 authorized; 512,943,561 shares issued and outstanding as of December 31, 2025)	8.9	5.1
Additional paid-in capital	7,719.8	7,121.5
Accumulated other comprehensive loss	(73.7)	(42.2)
Accumulated deficit	(9,107.7)	(8,979.2)
Total stockholders' deficit	(1,452.7)	(1,894.8)
Total liabilities and stockholders' deficit	<u>\$ 8,043.6</u>	<u>\$ 8,017.8</u>

See Notes to Condensed Consolidated Financial Statements.

AMC ENTERTAINMENT HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions)	Six Months Ended	
	June 30, 2026	June 30, 2025
Cash flows from operating activities:	(unaudited)	
Net loss	\$ (128.5)	\$ (206.8)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:		
Depreciation and amortization	151.8	153.9
Loss on extinguishment of debt	63.1	—
Gain on derivatives	(8.4)	(41.2)
Deferred income taxes	0.4	0.9
Gains on investments in Hycroft	(16.5)	(2.5)
Amortization of net discount on corporate borrowings to interest expense	5.5	8.6
Amortization of deferred financing costs to interest expense	10.1	3.9
PIK interest expense	30.9	17.1
Non-cash portion of stock-based compensation	10.6	11.7
Equity in earnings from non-consolidated entities, net of distributions	(4.0)	(0.1)
Lease incentives	24.6	8.9
Non-cash rent benefit	(58.5)	(53.0)
Net periodic pension cost	1.0	0.6
Change in assets and liabilities:		
Receivables	25.6	49.9
Other assets	(0.9)	(10.2)
Accounts payable	18.2	(87.5)
Accrued expenses and other liabilities	(26.2)	(50.4)
Other, net	8.1	(35.4)
Net cash provided by (used in) operating activities	106.9	(231.6)
Cash flows from investing activities:		
Capital expenditures	(91.5)	(96.5)
Proceeds from disposition of long-term assets	2.2	0.8
Proceeds from sale of Hycroft	29.7	—
Other, net	—	0.1
Net cash used in investing activities	(59.6)	(95.6)
Cash flows from financing activities:		
Net proceeds from equity issuances	334.6	169.6
Proceeds from issuance of Odeon Term Loans due 2031	416.5	—
Principal payments under Odeon Senior Secured Notes due 2027	(400.0)	—
Premium paid to extinguish Odeon Senior Secured Notes due 2027	(12.8)	—
Principal payments under Senior Subordinated Notes due 2025	—	(42.8)
Repurchase of Senior Subordinated Notes due 2025	—	(1.3)
Principal payments under finance lease obligations	(3.0)	(1.9)
Scheduled principal payments under term loan borrowings	(10.0)	(10.0)
Cash used to pay deferred financing costs	(24.0)	(0.1)
Taxes paid for restricted unit withholdings	(3.7)	(4.4)
Net cash provided by financing activities	297.6	109.1
Effect of exchange rate changes on cash and cash equivalents and restricted cash	(2.7)	12.4
Net increase (decrease) in cash and cash equivalents and restricted cash	342.2	(205.7)
Cash and cash equivalents and restricted cash at beginning of period	477.3	680.8
Cash and cash equivalents and restricted cash at end of period	\$ 819.5	\$ 475.1
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:		
Cash paid during the period for:		
Interest	\$ 193.0	\$ 190.3
Income taxes paid, net	\$ 3.5	\$ 2.8
Schedule of non-cash activities:		

[Table of Contents](#)

Construction payables at period end	\$	48.0	\$	38.6
Consent fees paid with shares of Common Stock	\$	34.5	\$	—
Other third-party equity issuance costs payable	\$	0.7	\$	—
Issuance of shares of Common Stock in Voluntary Exchange of Senior Secured				
Exchangeable Notes due 2030	\$	192.9	\$	—
Deferred financing costs payable	\$	1.5	\$	—

See Notes to Condensed Consolidated Financial Statements.

AMC ENTERTAINMENT HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2026
(Unaudited)

NOTE 1—BASIS OF PRESENTATION

AMC Entertainment Holdings, Inc. (“Holdings”), through its direct and indirect subsidiaries, including American Multi-Cinema, Inc. (“Multi-Cinema”) and its subsidiaries, (collectively with Holdings, unless the context otherwise requires, the “Company” or “AMC”), is principally involved in the theatrical exhibition business and owns, operates, or has interests in theatres located in the United States and Europe. The condensed consolidated financial statements include the accounts of Holdings and all subsidiaries and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. All significant intercompany balances and transactions have been eliminated in consolidation. The Company manages its business under two reportable segments for its theatrical exhibition operations, U.S. markets and International markets.

The accompanying condensed consolidated balance sheet as of December 31, 2025, which was derived from audited financial statements, and the unaudited condensed consolidated financial statements, have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by the accounting principles generally accepted in the United States of America for complete consolidated financial statements. In the opinion of management, these interim financial statements reflect all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of the Company’s financial position and results of operations. Due to the seasonal nature of the Company’s business, results for the six months ended June 30, 2026, are not necessarily indicative of the results to be expected for the year ending December 31, 2026.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Liquidity. The Company believes its existing cash and cash equivalents, together with cash generated from operations, will be sufficient to fund its operations and satisfy its obligations currently and through the next twelve months. The Company’s historical cash burn rates are not sustainable long-term. Based on the Company’s current cost structure, in order to achieve sustainable annual net positive cash flows from operating activities, the Company believes that revenues will need to be at least in line with pre-COVID-19 revenues. The Company has achieved net positive cash flows from operating activities for the six months ended June 30, 2026. Until such time as the Company is able to achieve annual sustainable net positive cash flows from operating activities, it is difficult to estimate the Company’s future cash burn rates and liquidity requirements. Depending on the Company’s assumptions regarding the timing and ability to achieve increased levels of revenue, the estimates of the required liquidity vary significantly.

There can be no assurance that the revenues, costs, attendance levels, and other assumptions used to estimate the Company’s liquidity requirements and future cash burn rates will be correct, and the ability to be predictive is uncertain due to limited ability to predict studio film release dates, the overall production and theatrical release levels, and success of individual titles. Further, there can be no assurances that the Company will be successful in generating the additional liquidity necessary to meet the Company’s obligations beyond twelve months from the issuance of these financial statements on terms acceptable to the Company or at all.

The Company expects, from time to time, to continue to seek to retire or purchase its outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. The Company continuously monitors the capital markets and its capital structure, and may, from time to time, seek to refinance, amend or otherwise restructure its outstanding debt on an opportunistic basis. Such repurchases, refinancings, amendments, restructurings or exchanges, if any, will be upon such terms and at such prices as it may determine, and will depend on prevailing market conditions, its liquidity requirements, the availability of authorized share capital, contractual restrictions and other factors. The amounts involved may be material and, to the extent equity

[Table of Contents](#)

is used, dilutive. Additionally, the Company has bolstered its liquidity through sales of its Class A Common Stock (“Common Stock”), see Note 6—Stockholders’ Deficit for further information on these sales.

Cash and Cash Equivalents. As of June 30, 2026, cash and cash equivalents for the U.S. markets and International markets were \$683.6 million and \$94.8 million, respectively, and as of December 31, 2025, cash and cash equivalents for the U.S. markets and International markets were \$302.6 million and \$125.9 million, respectively.

Restricted Cash. Restricted cash includes cash held in the Company’s bank accounts as a guarantee for certain landlords and cash collateralized letters of credit relating to the Company’s insurance and utilities programs. The following table provides a reconciliation of cash and cash equivalents and restricted cash reported in the condensed consolidated balance sheets to the total of the amounts in the condensed consolidated statements of cash flows.

(In millions)	As of	
	June 30, 2026	December 31, 2025
Cash and cash equivalents	\$ 778.4	\$ 428.5
Restricted cash	41.1	48.8
Total cash and cash equivalents and restricted cash in the statement of cash flows	\$ 819.5	\$ 477.3

As of June 30, 2026, restricted cash for the U.S. markets and International markets were \$15.3 million and \$25.8 million, respectively. As of December 31, 2025, restricted cash for the U.S. markets and International markets were \$20.5 million and \$28.3 million, respectively.

Investments. On February 5, 2026, the Company exercised its remaining warrants to purchase 1,000,824 common shares of Hycroft Mining Holding Corporation (“Hycroft”) on a cashless basis and received 765,440 common shares of Hycroft. During the six months ended June 30, 2026, the Company sold 700,000 common shares of Hycroft for \$29.7 million. As of June 30, 2026, the Company held 129,478 remaining common shares of Hycroft. The common shares are recorded at fair value at each reporting period and unrealized gains and losses are reported in investment income. The Company recorded unrealized losses related to its investments in Hycroft in investment income of \$1.5 million and \$0.3 million during the three months ended June 30, 2026 and June 30, 2025, respectively. The Company recorded realized and unrealized gains related to its investments in Hycroft in investment income of \$16.5 million and \$2.5 million during the six months ended June 30, 2026 and June 30, 2025, respectively.

Related Party Transactions. The Company conducts business with certain of its equity method investees in the ordinary course of business. Transactions primarily relate to advertising revenue and film exhibition costs for film rent. The below table summarizes the related party advertising revenues and film exhibition costs for the three and six months ended June 30, 2026 and June 30, 2025, respectively:

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Related party advertising revenues	\$ 10.2	\$ 6.1	\$ 15.6	\$ 11.2
Related party film exhibition costs	8.2	5.8	14.5	9.3

Accumulated Other Comprehensive Loss. The following table presents the change in accumulated other comprehensive loss by component:

(In millions)	Foreign Currency	Pension Benefits	Total
Balance December 31, 2025	\$ (38.3)	\$ (3.9)	\$ (42.2)
Other comprehensive income (loss)	(31.7)	0.2	(31.5)
Balance June 30, 2026	\$ (70.0)	\$ (3.7)	\$ (73.7)

Accumulated Depreciation. Accumulated depreciation related to property was \$3,606.1 million and \$3,532.6 million as of June 30, 2026, and December 31, 2025, respectively.

Other Expense (Income). The following table sets forth the components of other expense (income):

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Foreign currency transaction losses (gains)	\$ (0.4)	\$ (23.9)	\$ 8.6	\$ (36.9)
Governmental assistance - International markets	(0.5)	(10.3)	(0.5)	(10.5)
Net periodic pension cost	0.5	0.3	1.0	0.6
Loss on extinguishment - Senior Secured Exchangeable Notes due 2030	33.0	—	33.0	—
Loss on extinguishment - Odeon Senior Secured Notes due 2027	30.1	—	30.1	—
Debt modifications - third party fees	—	—	0.3	—
Increase (decrease) in fair value of bifurcated embedded derivative - 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	9.8	3.9	2.7	(41.2)
Increase (decrease) in fair value of bifurcated embedded derivative - Senior Secured Exchangeable Notes due 2030	41.3	—	(11.1)	—
Equity in earnings of non-consolidated entities	(4.0)	(2.1)	(6.7)	(2.9)
Business interruption insurance recoveries	(0.2)	—	(0.2)	—
Total other expense (income)	<u>\$ 109.6</u>	<u>\$ (32.1)</u>	<u>\$ 57.2</u>	<u>\$ (90.9)</u>

NOTE 2—LEASES

The following table reflects the lease costs for the periods presented:

(In millions)	Consolidated Statements of Operations	Three Months Ended		Six Months Ended	
		June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Operating lease cost					
Theatre properties	Rent	\$ 193.5	\$ 193.4	\$ 385.6	\$ 383.6
Theatre properties	Operating expense	1.5	2.2	2.8	3.4
Equipment	Operating expense	12.8	10.4	25.4	20.1
Office and other	General and administrative: other	1.2	1.4	2.4	2.7
Finance lease cost					
Amortization of finance lease assets	Depreciation and amortization	0.9	0.7	1.6	1.4
Interest expense on lease liabilities	Interest expense	0.9	0.8	1.7	1.6
Variable operating and finance lease cost					
Theatre properties	Rent	30.3	29.2	62.3	57.1
Theatre properties	Interest expense	0.9	0.6	1.5	1.0
Equipment	Operating expense	24.6	22.6	39.2	32.0
Total lease cost		\$ 266.6	\$ 261.3	\$ 522.5	\$ 502.9

[Table of Contents](#)

Cash flow and supplemental information are presented below:

(In millions)	Six Months Ended	
	June 30, 2026	June 30, 2025
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows used in finance leases	\$ (1.4)	\$ (1.4)
Operating cash flows used in operating leases	(479.4)	(461.8)
Financing cash flows used in finance leases	(3.0)	(1.9)
Lease incentives:		
Operating cash flows provided by operating leases	24.6	8.9
Supplemental disclosure of noncash leasing activities:		
Right-of-use assets obtained in exchange for new operating lease liabilities (1)	69.6	192.4
Right-of-use assets obtained in exchange for new finance lease liabilities (1)	5.4	—

(1) Includes lease extensions and option exercises.

The following table represents the weighted-average remaining lease term and discount rate as of June 30, 2026:

Lease Term and Discount Rate	Weighted Average Remaining Lease Term (years)	Weighted Average Discount Rate
Operating leases	7.3	11.1%
Finance leases	11.8	6.2%

Minimum annual payments required under existing operating and finance leases and the net present value thereof as of June 30, 2026, are as follows:

(In millions)	Operating Lease Payments	Finance Lease Payments
Six months ending December 31, 2026	\$ 470.7	\$ 5.3
2027	901.5	10.4
2028	815.5	10.4
2029	711.0	8.8
2030	608.4	7.7
2031	503.5	6.5
Thereafter	1,505.1	26.7
Total lease payments	5,515.7	75.8
Less imputed interest	(1,704.7)	(23.2)
Total operating and finance lease liabilities, respectively	\$ 3,811.0	\$ 52.6

As of June 30, 2026, the Company had signed additional operating lease agreements for two theatres that have not yet commenced. The leases have terms ranging from 10 to 12 years and total lease payments of approximately \$24.3 million. The timing of the lease commencements is dependent on the applicable landlord providing the Company with control and access to the applicable theatre.

NOTE 3—REVENUE RECOGNITION

Disaggregation of Revenue. Revenue is disaggregated in the following tables by major revenue types and by timing of revenue recognition:

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Major revenue types				
Admissions	\$ 863.1	\$ 762.6	\$ 1,441.5	\$ 1,236.1
Food and beverage	576.1	499.6	923.4	783.0
Other theatre:				
Ticket fees	72.7	56.0	113.1	86.5
Advertising	43.3	37.8	80.6	68.4
Other	41.5	41.9	83.5	86.4
Other theatre	157.5	135.7	277.2	241.3
Total revenues	\$ 1,596.7	\$ 1,397.9	\$ 2,642.1	\$ 2,260.4

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Timing of revenue recognition				
Products and services transferred at a point in time	\$ 1,459.1	\$ 1,282.8	\$ 2,378.5	\$ 2,042.1
Products and services transferred over time (1)	137.6	115.1	263.6	218.3
Total revenues	\$ 1,596.7	\$ 1,397.9	\$ 2,642.1	\$ 2,260.4

(1) Amounts primarily include subscription and advertising revenues.

The following tables provide the balances of receivables, net and deferred revenues and income:

(In millions)	June 30, 2026	December 31, 2025
Current assets		
Receivables related to contracts with customers	\$ 49.1	\$ 95.1
Miscellaneous receivables	76.5	60.9
Receivables, net	\$ 125.6	\$ 156.0

(In millions)	June 30, 2026	December 31, 2025
Current liabilities		
Deferred revenues related to contracts with customers	\$ 446.7	\$ 462.4
Miscellaneous deferred income	5.9	3.1
Deferred revenues and income	\$ 452.6	\$ 465.5

The significant changes in contract liabilities with customers included in deferred revenues and income are as follows:

(In millions)		Deferred Revenues Related to Contracts with Customers
Balance December 31, 2025	\$	462.4
Cash received in advance (1)		214.1
Customer loyalty rewards accumulated, net of expirations:		
Admission revenues (2)		9.6
Food and beverage revenues (2)		26.4
Other theatre revenues (2)		—
Reclassification to revenue as the result of performance obligations satisfied:		
Admission revenues (3)		(177.1)
Food and beverage revenues (3)		(48.3)
Other theatre revenues (4)		(40.7)
Foreign currency translation adjustment		0.3
Balance June 30, 2026	\$	446.7

- (1) Includes movie tickets, food and beverage, gift cards, exchange tickets, subscription membership fees, and other loyalty membership fees.
- (2) Amount of rewards accumulated, net of expirations, that are attributed to loyalty programs.
- (3) Amount of revenue recognized from redemptions of gift cards, exchange tickets, movie tickets, and loyalty programs.
- (4) Amounts relate to income from non-redeemed or partially redeemed gift cards, non-redeemed exchange tickets, subscription membership fees, and loyalty program membership fees.

The significant changes to contract liabilities included in the exhibitor services agreement in the condensed consolidated balance sheets, are as follows:

(In millions)		Exhibitor Services Agreement (1)
Balance December 31, 2025	\$	459.1
Other theatre revenue recognized as performance obligations are satisfied		(3.2)
Balance June 30, 2026	\$	455.9

- (1) The exhibitor services agreement contract liability relates to National CineMedia, LLC (“NCM”) common units that were previously received under the exhibitor services agreement dated February 13, 2007 and amended and restated as of December 13, 2013. On April 17, 2025, NCM entered into the Second Amended and Restated Exhibitor Services Agreement (the “Amended ESA”) with the Company. The term of the Amended ESA has been extended by five years through February 13, 2042. The Company treated the Amended ESA as a contract modification pursuant to *ASC 606 – Revenue from Contracts with Customers*. Accordingly, the Company has allocated the additional consideration received from the contract modification to the exhibitor services agreement contract liability and updated the discount rate used to account for the significant financing component to 16.12%. Prior to the contract modification, the weighted average discount rate used to account for the significant financing component was approximately 7.5%. The contract liability will be reclassified to other theatre revenue over the new term of the Amended ESA as the remaining performance obligations are satisfied. The non-cash revenue resulting from the satisfaction of the performance obligations is adjusted for in the condensed consolidated statements of cash flows under the changes in accrued expenses and other liabilities caption.

Gift Cards and Exchange Tickets. The total amount of non-redeemed gift cards and exchange tickets included in deferred revenues and income as of June 30, 2026 was \$305.8 million. This will be recognized as revenues as (i) the gift cards and exchange tickets are redeemed, (ii) the estimated non-redeemed gift card and exchange ticket revenues are recognized in proportion to the pattern of actual redemptions, which is estimated to occur over the next one to 36 months, or (iii) the gift cards or exchange tickets expire.

Loyalty Programs. As of June 30, 2026, the amount of deferred revenues related to loyalty programs included

in deferred revenues and income was \$98.6 million. The earned points will be recognized as revenue as the points are redeemed, expire, or as changes in estimated non-redemption rates occur. Subscription membership fees and loyalty membership fees are recognized ratably over their respective membership periods.

The Company applies the practical expedient in ASC 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.

NOTE 4—GOODWILL

The following table summarizes the changes in goodwill by reporting unit for the six months ended June 30, 2026:

(In millions)	U.S. Markets			International Markets			Consolidated Goodwill		
	Gross Carrying Amount	Accumulated Impairment Losses	Net Carrying Amount	Gross Carrying Amount	Accumulated Impairment Losses	Net Carrying Amount	Gross Carrying Amount	Accumulated Impairment Losses	Net Carrying Amount
Balance December 31, 2025	\$ 3,072.6	\$ (1,276.1)	\$ 1,796.5	\$ 1,705.2	\$ (1,085.6)	\$ 619.6	\$ 4,777.8	\$ (2,361.7)	\$ 2,416.1
Currency translation adjustment	—	—	—	(57.2)	18.7	(38.5)	(57.2)	18.7	(38.5)
Balance June 30, 2026	\$ 3,072.6	\$ (1,276.1)	\$ 1,796.5	\$ 1,648.0	\$ (1,066.9)	\$ 581.1	\$ 4,720.6	\$ (2,343.0)	\$ 2,377.6

NOTE 5—CORPORATE BORROWINGS AND FINANCE LEASE LIABILITIES

A summary of the carrying value of corporate borrowings and finance lease liabilities is as follows:

(In millions)	June 30, 2026	December 31, 2025
Secured Debt:		
Credit Agreement-Term Loans due 2029 (10.639% as of June 30, 2026 and 10.731% as of December 31, 2025)	\$ 1,984.2	\$ 1,994.2
Odeon Credit Agreement-10.5% Term Loans due 2031	425.0	—
Senior Secured Notes due 2029 (9.0% cash interest & 6.0% PIK interest as of June 30, 2026 and December 31, 2025)	903.4	877.1
6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	116.1	111.6
7.5% First Lien Notes due 2029	360.0	360.0
Unsecured/Retired Debt:		
6.125% Senior Subordinated Notes due 2027	125.5	125.5
12.75% Odeon Senior Secured Notes due 2027	—	400.0
Senior Secured Exchangeable Notes due 2030 (1.5% cash interest)	—	155.8
Total principal amount of corporate borrowings	\$ 3,914.2	\$ 4,024.2
Finance lease liabilities	52.6	52.5
Accrued paid-in-kind interest	2.8	2.7
Deferred financing costs	(75.8)	(64.4)
Net discount (1)	(4.9)	(68.5)
Bifurcated embedded derivative – Senior Secured Exchangeable Notes due 2030	—	131.9
Bifurcated embedded derivative – 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030	15.3	12.6
Total carrying value of corporate borrowings and finance lease liabilities	\$ 3,904.2	\$ 4,091.0
Less:		
Current maturities of corporate borrowings	(148.9)	(19.9)
Current maturities of finance lease liabilities	(7.4)	(5.8)
Total noncurrent carrying value of corporate borrowings and finance lease liabilities	\$ 3,747.9	\$ 4,065.3

[Table of Contents](#)

(1) The following table provides details of the net discount of corporate borrowings:

(In millions)	June 30, 2026	December 31, 2025
12.75% Odeon Senior Secured Notes due 2027	\$ —	\$ (14.6)
Odeon Credit Agreement-10.5% Term Loans due 2031	(8.2)	—
Senior Secured Notes due 2029	55.6	62.5
Senior Secured Exchangeable Notes due 2030	—	(57.4)
Credit Agreement-Term Loans due 2029	(27.2)	(32.6)
6.00%/8.00% Cash/PIK/Toggle Senior Secured Exchangeable Notes due 2030	(25.1)	(26.4)
Net discount	<u>\$ (4.9)</u>	<u>\$ (68.5)</u>

The following table provides the principal payments required and maturities of corporate borrowing as of June 30, 2026:

(In millions)	Principal Amount of Corporate Borrowings
Six months ended December 31, 2026 (1)	\$ 137.5
2027	23.9
2028	23.7
2029	3,202.8
2030	120.4
2031	405.9
Total	<u>\$ 3,914.2</u>

(1) Includes \$125.5 million for the 6.125% Senior Subordinated Notes due 2027 (the “Senior Subordinated Notes due 2027”) that will be redeemed pursuant to the Notice (as defined herein).

Debt Repurchases

The table below summarizes the various cash debt repurchase transactions during the six months ended June 30, 2025.

(In millions)	Aggregate Principal Repurchased	Reacquisition Cost	(Gain)/Loss on Extinguishment	Accrued Interest Paid
5.75% Senior Subordinated Notes due 2025	\$ 1.3	\$ 1.3	\$ —	\$ —

The total carrying value of the debt extinguished in the above transactions during the six months ended June 30, 2025 was \$1.3 million.

6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030

(In millions)	Carrying Value as of December 31, 2025	(Increase) Decrease to Net Earnings (Loss)	Carrying Value as of June 30, 2026
Principal balance	\$ 111.6	\$ 4.5	\$ 116.1
Discount	(26.4)	1.3	(25.1)
Debt issuance costs	(5.2)	0.2	(5.0)
Accrued paid-in-kind interest	0.4	—	0.4
Bifurcated embedded derivative	12.6	2.7	15.3
Carrying value	<u>\$ 93.0</u>	<u>\$ 8.7</u>	<u>\$ 101.7</u>

The 6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030 (the “Existing Exchangeable Notes”) have an effective interest rate of 15.12%.

Senior Secured Exchangeable Notes due 2030

(In millions)	Carrying Value as of December 31, 2025	(Increase) Decrease to Net Earnings (Loss)	Deferred Charges Activity	Consent Fee Paid With Common Stock	Notes Exchanged For Common Stock	Carrying Value as of June 30, 2026
Principal balance	\$ 155.8	\$ —	\$ —	\$ —	\$ (155.8)	\$ —
Discount	(57.4)	3.4	—	—	54.0	—
Debt issuance costs	(14.8)	0.8	1.6	—	12.4	—
Bifurcated embedded derivative	131.9	(11.1)	(1.6)	(15.7)	(103.5)	—
Carrying value	<u>\$ 215.5</u>	<u>\$ (6.9)</u>	<u>\$ —</u>	<u>\$ (15.7)</u>	<u>\$ (192.9)</u>	<u>\$ —</u>

The Senior Secured Exchangeable Notes due 2030 (the “New Exchangeable Notes”) had an effective interest rate of 16.54%. On March 23, 2026, the Company issued 15,378,194 shares of Common Stock for consent fees payable to the holders of the New Exchangeable Notes. The consent fees were paid as consideration for the 2025 Refinancing Transactions (as defined herein) and amendments made to the indenture governing the New Exchangeable Notes. The consent fees had previously been included as part of the bifurcated embedded derivative for the New Exchangeable Notes.

On May 4 and May 11, 2026, the holders of the New Exchangeable Notes (the “Exchanging Noteholders”) issued by Muvico, LLC, a wholly owned subsidiary of the Company (“Muvico”), delivered Notices of Voluntary Exchange to Muvico and GLAS Trust Company LLC, as exchange agent, to exchange all \$155,845,562 aggregate principal amount of New Exchangeable Notes outstanding for shares of Common Stock, pursuant to the terms of the indenture governing the New Exchangeable Notes (the “Indenture”). The Company settled the exchange (the “Exchange”) by issuing an aggregate of 142,102,295 shares of Common Stock to the Exchanging Noteholders (including shares issued in respect of the Exchange Adjustment Consideration (as defined in the Indenture) and \$0.9 million accrued and unpaid interest). The Company treated the Exchange as an extinguishment of the New Exchangeable Notes (including the bifurcated embedded derivative liability for the embedded conversion features) and recorded a loss on extinguishment of \$33.0 million. The Company adjusted the bifurcated embedded derivative liability to fair value immediately prior to the Exchange and recorded \$41.3 million of expense during the three months ended June 30, 2026. During the six months ended June 30, 2026, the Company recorded \$(11.1) million of other income related to the decrease in the fair value of the bifurcated embedded derivative liability. As a result of the Exchange, all remaining New Exchangeable Notes were cancelled in accordance with the Indenture.

New 2029 Notes Amendments

On February 12, 2026, and February 24, 2026, Holdings, Muvico and certain holders of Muvico’s new Senior Secured Notes due 2029 (the “New 2029 Notes”) (such holders, the “New 2029 Noteholders”) agreed to amend the indenture governing the New 2029 Notes (the “2029 Notes Indenture”). The amendments (the “Indenture Amendments”) among other things, provide the Company with flexibility to:

- refinance its outstanding term loan credit agreement and 12.75% Senior Secured Notes due 2027 (the “Odeon Notes due 2027”) issued by Odeon Finco PLC (“Odeon Finco”), a wholly-owned direct subsidiary of Odeon Cinemas Group Limited (“OCGL”) and an indirect subsidiary of Holdings, with new debt that may be secured and guaranteed by Holdings, OCGL, and Muvico, and
- at any time that there are no New Exchangeable Notes outstanding, incur up to an additional \$50 million of secured debt under the New 2029 Notes Indenture.

In consideration for the New 2029 Noteholders’ agreement to the Indenture Amendments, the Company issued 17,739,549 shares of Common Stock as a consent fee. The Indenture Amendments were treated as a modification of the New 2029 Notes and the Company recorded \$18.8 million to deferred financing costs and to stockholder’s deficit for the consent fees paid in shares.

Odeon Credit Agreement & Odeon Notes Redemption

On April 17, 2026, Odeon Finco, a wholly-owned direct subsidiary of OCGL and an indirect subsidiary of Holdings, entered into a Credit Agreement (the “Odeon Credit Agreement”), by and among Odeon Finco, as borrower, OCGL, as the company, the lenders party thereto and U.S. Bank Trust Company, National Association, as administrative agent and security agent, pursuant to which Odeon Finco borrowed \$425.0 million of new term loans maturing in 2031 (the “Odeon Term Loans due 2031”). The proceeds from the Odeon Term Loans due 2031 and approximately \$38.2 million of cash from the balance sheet were used to fund the full redemption (the “Odeon Notes Redemption”) of Odeon Finco’s outstanding Odeon Notes due 2027 and to pay related fees, costs, premiums and expenses, including approximately \$23.5 million of interest due on the Odeon Notes due 2027. In connection with the Odeon Notes Redemption, the Odeon Notes due 2027 have been delisted from the Official List of The International Stock Exchange. The Company treated the Odeon Notes Redemption as an extinguishment of debt and recorded a \$30.1 million loss on extinguishment. The Odeon Term Loans due 2031 were issued with a 2.0% discount (\$8.5 million) and the Company incurred \$21.4 million of debt issuance costs. The discount and debt issuance costs will be amortized to interest expense over the term of the Odeon Term Loans due 2031 using the effective interest method.

Interest, Amortization, Guarantees and Security

The Odeon Credit Agreement provides for the Odeon Term Loans due 2031 in an initial aggregate principal amount of \$425.0 million and which mature on April 17, 2031. The Odeon Term Loans due 2031 bear interest at a fixed 10.50% interest rate and are subject to amortization of principal, payable in quarterly installments on the fifteenth day of each April, July, October and January (commencing on July 15, 2026), equal to 1.00% of the principal balance on April 17, 2026 per annum. The remaining aggregate principal amount outstanding (together with accrued and unpaid interest on the principal amount) of the Odeon Term Loans due 2031 is payable at maturity.

The Odeon Term Loans due 2031 are, subject to limited exceptions, fully and unconditionally guaranteed on a joint and several basis by OCGL and certain subsidiaries of OCGL (the “OCGL Subsidiaries”). The Odeon Term Loans due 2031 are also fully and unconditionally guaranteed by Holdings, on a standalone and unsecured basis, pursuant to the terms of a Guarantee Agreement dated as of April 17, 2026 between Holdings and U.S. Bank Trust Company, National Association (the “AMC Guaranty”).

The Odeon Term Loans due 2031 are secured by OCGL and the OCGL Subsidiaries on a first-priority basis by (i) a fixed charge or security interest, as applicable, over the shares of Odeon Finco, OCGL and certain of the OCGL Subsidiaries; (ii) an assignment of rights held by Odeon Finco under a proceeds loan agreement between Odeon Finco and OCGL with respect to the proceeds of the Odeon Term Loans due 2031; (iii) a fixed charge or security interest, as applicable, over certain bank accounts, intercompany receivables, intellectual property rights and other assets of Odeon Finco, OCGL and certain of the OCGL Subsidiaries; and (iv) a floating charge over substantially all other assets of Odeon Finco, OCGL and certain of the OCGL Subsidiaries that are incorporated in England and Wales. Holdings has not pledged any of its assets to secure the Odeon Term Loans due 2031 or the related guarantees and the AMC Guaranty does not benefit from any security interest over the collateral or any other asset.

Covenants and Events of Default

The Odeon Credit Agreement contains covenants that limit OCGL and the OCGL Subsidiaries’ ability to, among other things: (i) incur additional indebtedness or guarantee indebtedness; (ii) create liens; (iii) declare or pay dividends, redeem stock or make other distributions to stockholders; (iv) make investments; (v) enter into transactions with its affiliates; (vi) consolidate, merge, sell or otherwise dispose of all or substantially all of their respective assets; and (vii) maintain cash in the accounts of OCGL and the OCGL Subsidiaries. These covenants are subject to a number of important limitations and exceptions. The Odeon Credit Agreement also provides for events of default, which, if any of them occur, would permit or require the principal, premium, if any, interest and any other monetary obligations on all the then outstanding Odeon Term Loans due 2031 to become immediately due and payable.

Second Amendment to Muvico Credit Agreement

In connection with the Odeon Credit Agreement, on April 17, 2026, Holdings, as borrower, Muvico, as borrower, and Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent, entered into a Second Amendment (the “Second Amendment”) to the Credit Agreement dated as of July 22, 2024 (the “Muvico Credit Agreement”), as amended by the First Amendment to Muvico Credit Agreement, dated as of July 24, 2025, by and among Holdings, as borrower, Muvico, as borrower, the lenders party thereto and Wilmington Savings Fund Society, FSB, as

administrative agent and collateral agent.

The Second Amendment, among other things, amends the Muvico Credit Agreement to update the existing covenants and include additional covenants to make them as restrictive as those in the Odeon Credit Agreement.

2027 Notes Redemption Notice

Concurrently with the completion of the Offering (as defined herein), on June 24, 2026, the Company delivered a notice of full redemption (the “Notice”) to holders of its \$125.5 million aggregate principal amount of Senior Subordinated Notes due 2027 to redeem the Senior Subordinated Notes due 2027 in full at a redemption price equal to 100.000% of the principal amount of the Senior Subordinated Notes due 2027, plus accrued and unpaid interest, if any, to July 24, 2026, the redemption date.

Covenant Compliance

As of June 30, 2026, the Company believes that it was in full compliance with all agreements, including related covenants, governing its outstanding debt.

NOTE 6—STOCKHOLDERS’ DEFICIT

Share Issuances

In June 2026, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”) for the sale of 95,250,000 shares of Common Stock in a registered direct offering (the “Offering”), at a purchase price of \$2.10 per share. The Offering closed on June 24, 2026.

In connection with the Offering, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) on June 23, 2026 with Roth Capital Partners, LLC (the “Placement Agent”), as exclusive placement agent in connection with the Offering. As compensation to the Placement Agent, the Company paid the Placement Agent a cash fee of 5.5% of the aggregate gross proceeds raised in the Offering and reimbursed certain expenses.

The below table summarizes the activity during the six months ended June 30, 2026 related to the Offering:

(In millions)	Six Months Ended June 30, 2026	
Shares issued direct offering		95.3
Direct offering gross proceeds	\$	200.0
Placement fees paid	\$	11.0
Other third-party issuance costs incurred	\$	0.2
Other third-party issuance costs paid	\$	0.2

In February 2026, the Company entered into a sales and registration agreement (the “2026 Sales and Registration Agreement”) with Goldman Sachs & Co. LLC, B. Riley Securities, Inc. and Yorkville Securities, LLC, from time to time acting as sales agents (in such capacity, the “Sales Agents”) relating to shares of Common Stock of the Company having an aggregate offering price of up to \$150.0 million.

In accordance with the terms of the 2026 Sales and Registration Agreement, the Company issued and sold shares of Common Stock covered by the prospectus supplement from time to time through the Sales Agents. The Sales Agents acted as agents on the Company’s behalf or purchase shares of Common Stock from the Company as principal for its own account.

[Table of Contents](#)

The below table summarizes the activity of the various “at-the-market” offerings for the six months ended June 30, 2026 and June 30, 2025:

(In millions)	Six Months Ended	
	June 30, 2026	June 30, 2025
Shares issued through at-the-market offering	105.3	17.1
At-the-market offering gross proceeds	\$ 150.0	\$ 63.0
Sales agent fees paid	\$ 3.0	\$ 0.6
Other third-party issuance costs incurred	\$ 1.9	\$ 0.3
Other third-party issuance costs paid	\$ 1.2	\$ 1.5

Additionally in May 2026, the Company issued 142,102,295 shares of Common Stock to settle the Exchange of its New Exchangeable Notes. See Note 5—Corporate Borrowings and Finance Lease Liabilities for further information.

In December 2024, the Company entered into forward sales to sell 30,000,000 shares of Common Stock in the aggregate. The shares underlying the forward sales were issued in December 2024. The Company evaluated the forwards under *ASC 815—Derivatives and Hedging* and concluded that the transactions consist of a subscription receivable accounted for under ASC 505-10-45-2 reflecting the Company’s right to receive prepayments and to deliver shares to the forward counterparty. Accordingly, pursuant to Regulation S-X Rule 5-02.29, the Company recorded the prepayment as an increase to additional paid-in capital with an equal and offsetting subscription receivable as a decrease to additional paid-in capital. The subscription receivable was considered a debt-like host and the Company’s right to receive additional cash consideration up to a cap price based on the movement of the share price during a valuation period is an embedded feature that meets the definition of a derivative that meets the equity classification scope exception in ASC 815-40 and is not accounted for outside of equity.

In January 2025, the Company was paid \$108.7 million for prepayments in respect of the forwards. The Company reduced the subscription receivable which resulted in an increase in total additional paid-in capital. The valuation period ended on March 17, 2025 with no additional consideration owed to the Company.

Stock-Based Compensation

Equity Incentive Plans

On June 5, 2024, the Company’s shareholders approved a new equity incentive plan (“2024 EIP”). Awards that may be granted under the 2024 EIP include options, stock appreciation rights, restricted stock awards, restricted stock units (“RSUs”), performance stock units (“PSUs”), cash awards, and other equity-based awards. The 2024 EIP will be unlimited in duration and, in the event of termination, will remain in effect as long as any shares of awards under it are outstanding and not fully vested.

Awards Granted

The compensation committee of AMC’s board of directors (“Compensation Committee”) has granted awards of stock, RSUs, and PSUs to certain of the Company’s employees and directors under the 2024 EIP. Each RSU or PSU is convertible into one share of Common Stock upon vesting.

Each RSU and PSU held by a participant as of a dividend record date is entitled to a dividend equivalent equal to the amount paid with respect to one share of Common Stock underlying the unit. Any such accrued dividend equivalents are paid to the holder only upon vesting of the units. The grant date fair value of the awards is based on the closing share price of the Company’s Common Stock on such grant date.

The awards granted under the Company’s equity incentive plan generally have the following features:

- **Board of Directors Stock Awards:** On February 19, 2026, the Company granted 869,571 fully vested shares of Common Stock to the independent members of the Company’s board of directors with a grant date fair value of \$1.1 million.
- **Restricted Stock Unit Awards:** Each vested RSU will be settled by delivery of a single share of the Company’s Common Stock and therefore accounted for as equity instruments. Awards are generally

settled as each individual tranche vests under the relevant agreements. The Company records stock-based compensation expense on a straight-line recognition method over the requisite service period. The RSUs vest over three years, with one-third vesting each year. These RSUs will be settled within 30 days of vesting.

- **Performance Stock Unit Awards:** PSU awards are granted to certain members of management and executive officers. The total PSUs are divided into three separate year tranches, with each tranche allocated to a fiscal year within the performance period ("Tranche Year"). The PSUs within each Tranche Year are further divided between three performance targets: the Adjusted EBITDA performance target, the free cash flow performance target, and a target based upon various strategic initiatives. The PSU awards will vest if 80% to 120% of the performance targets are attained, with the corresponding vested unit amount ranging from 50% to 200% of the PSUs awarded. The 2026 Tranche Year strategic initiative based 2025 PSU awards will vest if four to ten two-year strategic initiatives are achieved by the end of the 2026 Tranche Year, with the corresponding vested unit amount ranging from 50% to 200% of the PSUs awarded.

The Compensation Committee establishes the annual performance targets at the beginning of each year. Therefore, in accordance with *ASC 718, Compensation - Stock Compensation*, the grant date (and fair value measurement date) for each Tranche Year is the date at the beginning of each year when a mutual understanding of the key terms and conditions are reached.

Special Awards

On February 19, 2026, the Compensation Committee approved modification of the performance goals applicable to the 2025 Tranche Year Adjusted EBITDA and free cash flow PSU awards. This was accounted for as a modification to the 2025 Tranche Year PSU awards which lowered the Adjusted EBITDA and free cash flow performance targets such that 200% vesting was achieved. This modification resulted in the immediate vesting of an additional 3,778,642 2025 Tranche Year PSUs. This was treated as a Type 3 modification (improbable-to-probable) which required the Company to recognize additional stock compensation expense based on the modification date fair values of the incremental PSUs. During the six months ended June 30, 2026, the Company recognized \$4.6 million of stock compensation expense related to these awards.

On February 19, 2025, the Compensation Committee approved modification of the performance goals applicable to all 2024 Tranche Year PSU awards. This was accounted for as a modification to the 2024 Tranche Year PSU awards which lowered the Adjusted EBITDA performance target such that 146% vesting was achieved. This modification resulted in the immediate vesting of an additional 270,093 of the 2024 Tranche Year PSUs (4,181 cash settled units and 265,912 equity settled units). This was treated as a Type 3 modification (improbable-to-probable) which required the Company to recognize additional stock compensation expense based on the modification date fair values of the incremental PSUs. During the six months ended June 30, 2025, the Company recognized \$1.0 million of stock compensation expense related to these awards.

Stock-Based Compensation Expense

The following table presents the stock-based compensation expense recorded within general and administrative: other:

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Special awards expense	\$ —	\$ —	\$ 4.6	\$ 1.0
Board of director stock award expense	—	—	1.1	1.3
Restricted stock unit expense	1.5	3.6	2.9	6.2
Performance stock unit expense	1.8	2.4	2.0	3.2
Total stock-based compensation expense	<u>\$ 3.3</u>	<u>\$ 6.0</u>	<u>\$ 10.6</u>	<u>\$ 11.7</u>

As of June 30, 2026, the estimated remaining unrecognized compensation cost related to stock-based compensation grants was approximately \$7.5 million, which reflects assumptions related to attainment of performance targets based on the scales as described below. The weighted average period over which this remaining compensation expense is expected to be recognized is approximately ten months. The Company accounts for forfeitures when they occur.

Nonvested Awards

The following table represents the equity classified nonvested RSU and PSU activity for the six months ended June 30, 2026:

	RSUs		PSUs	
	Number of RSUs	Weighted Average Grant Date Fair Value	Number of PSUs	Weighted Average Grant Date Fair Value
Nonvested at December 31, 2025	4,573,078	\$ 4.73	324,969	\$ 3.57
Granted (1)	—	—	3,448,938	1.24
Granted - Special Award	—	—	3,778,642	1.22
Vested	(942,900)	5.82	(119,307)	3.57
Vested - Special Award	—	—	(2,005,981)	1.22
Cancelled (2)	(882,087)	5.95	(97,339)	3.57
Cancelled - Special Award (2)	—	—	(1,772,661)	1.22
Nonvested at June 30, 2026	2,748,091	3.96	3,557,261	1.35
Tranche Year 2027 awarded under the 2025 PSU award with grant date fair values to be determined in year 2027 (3)	—	—	1,213,279	—
Total nonvested at June 30, 2026	<u>2,748,091</u>	—	<u>4,770,540</u>	—

- (1) The number of PSUs granted under the 2026 Tranche Year assumes the Company will vest at 185% for the Adjusted EBITDA performance target, 200% for the free cash flow performance target, and 133% for the strategic initiatives performance target.
- (2) Represents vested RSUs and PSUs surrendered in lieu of taxes. As a result, the Company paid taxes for restricted unit withholdings of approximately \$3.7 million during the six months ended June 30, 2026.
- (3) Assumes PSUs will vest at 100% of targets.

**Condensed Consolidated Statements of Stockholders' Deficit
For the Six Months Ended June 30, 2026**

(In millions, except share data)	Class A Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Stockholders' Deficit
	Shares	Amount				
Balances December 31, 2025	512,943,561	\$ 5.1	\$ 7,121.5	\$ (42.2)	\$ (8,979.2)	\$ (1,894.8)
Net loss	—	—	—	—	(117.1)	(117.1)
Other comprehensive loss	—	—	—	(15.5)	—	(15.5)
Taxes paid for restricted unit withholdings	—	—	(3.7)	—	—	(3.7)
Consent fees paid in shares	33,117,743	0.3	34.2	—	—	34.5
Shares issued through at-the-market offerings	55,224,032	0.6	62.2	—	—	62.8
Stock-based compensation (1)	3,937,759	0.1	7.2	—	—	7.3
Balances March 31, 2026	605,223,095	\$ 6.1	\$ 7,221.4	\$ (57.7)	\$ (9,096.3)	\$ (1,926.5)
Net loss	—	—	—	—	(11.4)	(11.4)
Other comprehensive loss	—	—	—	(16.0)	—	(16.0)
Shares issued through at-the-market offerings	50,029,248	0.5	81.8	—	—	82.3
Shares issued through registered direct offering	95,250,000	0.9	187.9	—	—	188.8
Shares issued upon exchange of New Exchangeable Notes	142,102,295	1.4	225.4	—	—	226.8
Stock-based compensation	—	—	3.3	—	—	3.3
Balances June 30, 2026	892,604,638	\$ 8.9	\$ 7,719.8	\$ (73.7)	\$ (9,107.7)	\$ (1,452.7)

(1) Includes 869,571 Common Stock shares awarded to the board of directors, and 3,068,188 vested Common Stock RSUs and PSUs.

**Condensed Consolidated Statements of Stockholders' Deficit
For the Six Months Ended June 30, 2025**

(In millions, except share data)	Class A Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total Stockholders' Deficit
	Shares	Amount				
Balances December 31, 2024	414,417,797	\$ 4.1	\$ 6,714.2	\$ (132.0)	\$ (8,346.8)	\$ (1,760.5)
Net loss	—	—	—	—	(202.1)	(202.1)
Other comprehensive income	—	—	—	52.7	—	52.7
Taxes paid for restricted unit withholdings	—	—	(4.4)	—	—	(4.4)
Shares issued and proceeds received through at-the-market offerings and forward agreements	17,052,756	0.2	170.6	—	—	170.8
Stock-based compensation (1)	1,673,008	—	5.7	—	—	5.7
Balances March 31, 2025	433,143,561	\$ 4.3	\$ 6,886.1	\$ (79.3)	\$ (8,548.9)	\$ (1,737.8)
Net loss	—	—	—	—	(4.7)	(4.7)
Other comprehensive income	—	—	—	11.1	—	11.1
Stock-based compensation	—	—	6.0	—	—	6.0
Balances June 30, 2025	433,143,561	\$ 4.3	\$ 6,892.1	\$ (68.2)	\$ (8,553.6)	\$ (1,725.4)

(1) Includes 370,586 Common Stock shares awarded to the board of directors and 1,302,422 vested Common Stock RSUs and PSUs.

NOTE 7—INCOME TAXES

The Company's worldwide effective income tax rate is based on actual income (loss), statutory rates, valuation allowances against deferred tax assets and tax planning opportunities available in the various jurisdictions in which it operates. The Company intends to compute quarterly tax expense based on an annual effective rate in future interim periods when more reliable estimates of annual income become available. The Company recognizes income tax-related interest expense and penalties as income tax expense and general and administrative expense, respectively.

The Company evaluates its deferred tax assets each period to determine if a valuation allowance is required based on whether it is "more likely than not" that some portion of the deferred tax assets would not be realized. The ultimate realization of these deferred tax assets is dependent upon the generation of sufficient taxable income during future periods on a federal, state, and foreign jurisdiction basis. The Company conducts its evaluation by considering all available positive and negative evidence, including historical operating results, forecasts of future profitability, the duration of statutory carryforward periods, and the outlooks for the U.S. motion picture and broader economy, among others.

A valuation allowance is recorded against the Company's U.S. deferred tax assets and most of the Company's international deferred tax assets as the Company has determined the realization of these assets does not meet the more likely than not criteria.

The effective tax rate for the six months ended June 30, 2026, reflects the impact of these valuation allowances against U.S. and international deferred tax assets generated during the period. The actual effective rate for the six months ended June 30, 2026, was (4.6)%. The Company's consolidated tax rate for the six months ended June 30, 2026, differs from the U.S. statutory tax rate primarily due to the valuation allowances in U.S. and foreign jurisdictions, foreign tax rate differences, federal and state tax credits, permanent differences and other discrete items.

NOTE 8—FAIR VALUE MEASUREMENTS

Fair value refers to the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the entity transacts business. The inputs used to develop these fair value measurements are established in a hierarchy, which ranks the quality and reliability of the information used to determine the fair values. The fair value classification is based on levels of inputs. Assets and liabilities that are carried at fair value are classified and disclosed in one of the following categories:

- Level 1: Quoted market prices in active markets for identical assets or liabilities.
- Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
- Level 3: Unobservable inputs that are not corroborated by market data.

Recurring Fair Value Measurements. The following table summarizes the Company's financial instruments carried at fair value on a recurring basis as of June 30, 2026:

(In millions)	Total Carrying Value at June 30, 2026	Fair Value Measurements at June 30, 2026 Using		
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Corporate Borrowings:				
Bifurcated embedded derivative - 6.00%/8.00% Cash/PIK				
Toggle Senior Secured Exchangeable Notes due 2030	\$ 15.3	\$ —	\$ —	\$ 15.3

6.00%/8.00% Cash/PIK Toggle Senior Secured Exchangeable Notes due 2030 embedded derivative. The Existing Exchangeable Notes have conversion features that required bifurcation from their respective host instruments pursuant to *ASC 815—Derivatives and Hedging*. The conversion features embedded within the notes were combined into a derivative that comprises all features requiring bifurcation. The embedded derivative has been valued using binomial lattice models. The binomial lattice models consist of simulated Common Stock prices from the valuation date to the maturity of the notes. The significant inputs used to value the derivative include the share price of the Common

[Table of Contents](#)

Stock, the volatility of the share price, time to maturity, risk-free interest rate, credit spread, and discount yield. The Company measures the derivative at fair value at the end of each reporting period with any changes in fair value recorded to other expense (income) in the condensed consolidated statements of operations.

Non-recurring Fair Value Measurements. The following table summarizes the fair value hierarchy of the bifurcated embedded derivative of the Senior Secured Exchangeable Notes due 2030 as of May 4, 2026:

(In millions)	Total Carrying Value at May 4, 2026	Fair Value Measurements at May 4, 2026 Using		
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Corporate Borrowings:				
Bifurcated embedded derivative - Senior Secured Exchangeable Notes due 2030	\$ 103.5	\$ —	\$ 103.5	\$ —

Senior Secured Notes due 2030 embedded derivative valuation technique. The embedded derivative was valued by determining the as-converted value of the New Exchangeable Notes and then subtracting the estimated fair value of the New Exchangeable Notes without the conversion feature. The as-converted value of the New Exchangeable Notes was calculated from the number of shares expected to be exchanged multiplied by the closing price of the Common Stock as of May 4, 2026. The estimated fair value of the New Exchangeable Notes without the conversion feature was determined using a discounted cash flow method using a discount yield derived from the risk-free rate and an interpolated credit spread.

Other Fair Value Measurement Disclosures. The Company is required to disclose the fair value of financial instruments that are not recognized at fair value in the statement of financial position for which it is practicable to estimate that value:

(In millions)	Total Carrying Value at June 30, 2026	Fair Value Measurements at June 30, 2026 Using		
		Quoted prices in active market (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Current maturities of corporate borrowings	\$ 148.9	\$ —	\$ 149.1	\$ —
Corporate borrowings (excluding derivatives)	3,687.4	—	3,784.7	—

Valuation Technique. Quoted market prices and observable market-based inputs were used to estimate fair value for Level 2 inputs. The Company valued these notes at principal value less an estimated discount reflecting a market yield to maturity. See Note 5—Corporate Borrowings and Finance Lease Liabilities for further information.

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value because of the short maturity of these instruments.

NOTE 9—SEGMENT REPORTING

The Company reports information about operating segments in accordance with *ASC 280-10, Segment Reporting*, which requires financial information to be reported based on the way management organizes segments within a company for making operating decisions and evaluating performance. Management has organized the Company around differences in geographic areas. The Company has identified two reportable segments for its theatrical exhibition operations, U.S. markets and International markets. The International markets reportable segment has operations in, or partial interest, in theatres in the United Kingdom, Germany, Spain, Italy, Ireland, Portugal, Sweden, Finland, Norway, and Denmark.

The measure of segment profit and loss the Company's chief operating decision maker uses to evaluate performance and allocate resources is Adjusted EBITDA. The Company defines Adjusted EBITDA as net earnings (loss) plus (i) income tax provision (benefit), (ii) interest expense and (iii) depreciation and amortization, as further adjusted to eliminate the impact of certain items that the Company does not consider indicative of the Company's ongoing operating performance and to include attributable EBITDA from equity investments in theatre operations in International markets. The Company does not report asset information by segment because that information is not used to evaluate the performance of or allocate resources between segments.

During the first quarter of 2026, the Company changed its definition of Adjusted EBITDA to adjust for net periodic pension cost. Net periodic pension cost is a recurring expense that includes several components such as service cost, interest cost, expected return on plan assets, amortization of prior service cost, and amortization of actuarial gains/losses. Additionally, the Company also includes infrequent gains and losses from benefit curtailments and settlements of pension obligations in net periodic pension cost. The Company no longer believes that net periodic pension cost should be included in Adjusted EBITDA as the pension plans are frozen, service cost is zero, and the remaining components are not indicative of ongoing operating performance as they are not driven by current operating decisions and largely depend on actuarial assumptions. While not the basis for this change, the revised definition further aligns the Company's definition of Adjusted EBITDA with the definition used in the Company's debt agreements. The adjustment for net periodic pension cost is included in the caption titled "other expense (income)" in the condensed consolidated statement of operations and in the reconciliation of net loss to Adjusted EBITDA further below. See the components of other expense (income) table in Note 1—Basis of Presentation for net periodic pension cost recorded in each period presented. All comparative period information for Adjusted EBITDA has been re-cast to conform with the current definition. The impact of this change on previously reported Adjusted EBITDA for the three and six months ended June 30, 2025 was an improvement of \$0.3 million and \$0.6 million, respectively.

The following tables below provide reconciliation of segment revenues to Adjusted EBITDA:

(In millions)	Three Months Ended June 30, 2026		
	U.S. Markets	International Markets	Consolidated
Revenues (1)	\$ 1,258.6	\$ 338.1	\$ 1,596.7
Less:			
Film exhibition costs	362.0	78.3	440.3
Food and beverage costs	79.7	28.0	107.7
Operating expense, excluding depreciation and amortization (2)	343.7	112.4	456.1
Rent	161.6	62.2	223.8
General and administrative expense - other, excluding depreciation and amortization (3)	26.0	22.7	48.7
Other segment items (4)	—	(1.3)	(1.3)
Adjusted EBITDA	\$ 285.6	\$ 35.8	\$ 321.4

[Table of Contents](#)

(In millions)	Three Months Ended June 30, 2025		
	U.S. Markets	International Markets	Consolidated
Revenues (1)	\$ 1,114.2	\$ 283.7	\$ 1,397.9
Less:			
Film exhibition costs	325.6	66.5	392.1
Food and beverage costs	72.8	23.3	96.1
Operating expense, excluding depreciation and amortization (2)	342.3	113.5	455.8
Rent	162.7	59.9	222.6
General and administrative expense - other, excluding depreciation and amortization (3)	29.5	22.7	52.2
Other segment items (4)	—	(10.4)	(10.4)
Adjusted EBITDA	<u>\$ 181.3</u>	<u>\$ 8.2</u>	<u>\$ 189.5</u>

(In millions)	Six Months Ended June 30, 2026		
	U.S. Markets	International Markets	Consolidated
Revenues (1)	\$ 1,999.4	\$ 642.7	\$ 2,642.1
Less:			
Film exhibition costs	548.6	147.3	695.9
Food and beverage costs	124.0	50.1	174.1
Operating expense, excluding depreciation and amortization (2)	637.0	226.7	863.7
Rent	324.0	123.9	447.9
General and administrative expense - other, excluding depreciation and amortization (3)	58.3	44.0	102.3
Other segment items (4)	—	(1.5)	(1.5)
Adjusted EBITDA	<u>\$ 307.5</u>	<u>\$ 52.2</u>	<u>\$ 359.7</u>

(In millions)	Six Months Ended June 30, 2025		
	U.S. Markets	International Markets	Consolidated
Revenues (1)	\$ 1,731.2	\$ 529.2	\$ 2,260.4
Less:			
Film exhibition costs	476.8	120.1	596.9
Food and beverage costs	113.8	39.5	153.3
Operating expense, excluding depreciation and amortization (2)	629.4	216.8	846.2
Rent	325.3	115.4	440.7
General and administrative expense - other, excluding depreciation and amortization (3)	61.7	40.8	102.5
Other segment items (4)	—	(11.0)	(11.0)
Adjusted EBITDA	<u>\$ 124.2</u>	<u>\$ 7.6</u>	<u>\$ 131.8</u>

- (1) All segment revenues are comprised of revenues from external customers.
- (2) Operating expense, excluding depreciation and amortization excludes certain expenses as further defined in the reconciliation of net loss to Adjusted EBITDA below.
- (3) General and administrative expense—other, excluding depreciation and amortization excludes stock compensation expense.
- (4) Other segment items include government assistance, business interruption insurance recoveries, and attributable EBITDA from International theatre joint ventures.

[Table of Contents](#)

Other segment disclosures:

(In millions)	Three Months Ended June 30, 2026		
	U.S. Markets	International Markets	Consolidated
Depreciation and amortization	\$ 57.3	\$ 18.8	\$ 76.1
Income tax provision	1.7	1.7	3.4
Other expense	84.7	28.9	113.6
Other significant noncash items:			
Stock-based compensation expense	2.9	0.4	3.3
Equity in earnings of non-consolidated entities	(3.4)	(0.6)	(4.0)
Capital expenditures	39.8	5.5	45.3

(In millions)	Three Months Ended June 30, 2025		
	U.S. Markets	International Markets	Consolidated
Depreciation and amortization	\$ 59.1	\$ 18.7	\$ 77.8
Income tax provision	0.5	0.7	1.2
Other expense (income)	4.3	(34.3)	(30.0)
Other significant noncash items:			
Stock-based compensation expense	5.4	0.6	6.0
Equity in earnings of non-consolidated entities	(2.0)	(0.1)	(2.1)
Capital expenditures	34.0	15.5	49.5

(In millions)	Six Months Ended June 30, 2026		
	U.S. Markets	International Markets	Consolidated
Depreciation and amortization	\$ 114.4	\$ 37.4	\$ 151.8
Income tax provision	2.2	3.4	5.6
Other expense	25.8	38.1	63.9
Other significant noncash items:			
Stock-based compensation expense	9.5	1.1	10.6
Equity in earnings of non-consolidated entities	(6.0)	(0.7)	(6.7)
Capital expenditures	74.5	17.0	91.5

(In millions)	Six Months Ended June 30, 2025		
	U.S. Markets	International Markets	Consolidated
Depreciation and amortization	\$ 117.9	\$ 36.0	\$ 153.9
Income tax provision	1.4	1.4	2.8
Other income	(40.4)	(47.6)	(88.0)
Other significant noncash items:			
Stock-based compensation expense	10.9	0.8	11.7
Equity in earnings of non-consolidated entities	(2.7)	(0.2)	(2.9)
Capital expenditures	65.8	30.7	96.5

[Table of Contents](#)

The following table sets forth a reconciliation of net loss to Adjusted EBITDA:

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Net loss	\$ (11.4)	\$ (4.7)	\$ (128.5)	\$ (206.8)
Plus:				
Income tax provision (1)	3.4	1.2	5.6	2.8
Interest expense	136.0	129.6	275.9	248.7
Depreciation and amortization	76.1	77.8	151.8	153.9
Certain operating expense (2)	2.3	2.6	2.0	5.4
Equity in earnings of non-consolidated entities (3)	(4.0)	(2.1)	(6.7)	(2.9)
Attributable EBITDA (4)	0.6	0.1	0.8	0.5
Investment expense (income) (5)	0.5	(1.4)	(17.8)	(7.1)
Other expense (income) (6)	114.3	(19.7)	64.6	(77.5)
Merger, acquisition and other costs (7)	0.3	0.1	1.4	3.1
Stock-based compensation expense (8)	3.3	6.0	10.6	11.7
Adjusted EBITDA	<u>\$ 321.4</u>	<u>\$ 189.5</u>	<u>\$ 359.7</u>	<u>\$ 131.8</u>

- (1) For information regarding the income tax provision, see Note 7—Income Taxes.
- (2) Amounts represent preopening expense related to temporarily closed screens under renovation, theatre and other closure expense for the permanent closure of screens, disposition of assets, and other non-operating gains or losses included in operating expenses. The Company has excluded these items as they are non-cash in nature or related to theatres that are not open.
- (3) Equity in earnings of non-consolidated entities during the three months ended June 30, 2026 primarily consisted of equity in earnings from AC JV, LLC (“AC JV”) of \$(3.3) million. Equity in earnings of non-consolidated entities during the three months ended June 30, 2025 primarily consisted of equity in earnings from AC JV of \$(1.8) million.

Equity in earnings of non-consolidated entities during the six months ended June 30, 2026 primarily consisted of equity in earnings from AC JV of \$(5.7) million. Equity in earnings of non-consolidated entities during the six months ended June 30, 2025 primarily consisted of equity in earnings from AC JV of \$(2.6) million.
- (4) Attributable EBITDA includes the EBITDA from equity investments in theatre operators in certain International markets. See below for a reconciliation of the Company’s equity in (earnings) of non-consolidated entities to attributable EBITDA. Because these equity investments are in theatre operators in regions where the Company holds a significant market share, the Company believes attributable EBITDA is more indicative of the performance of these equity investments and management uses this measure to monitor and evaluate these equity investments.

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Equity in (earnings) of non-consolidated entities	\$ (4.0)	\$ (2.1)	\$ (6.7)	\$ (2.9)
Less:				
Equity in (earnings) of non-consolidated entities excluding International theatre joint ventures	(3.5)	(2.2)	(6.2)	(3.0)
Equity in earnings (loss) of International theatre joint ventures	0.5	(0.1)	0.5	(0.1)
Income tax benefit	—	(0.1)	—	(0.1)
Investment income	(0.1)	—	(0.1)	—
Interest expense	—	0.1	—	0.1
Depreciation and amortization	0.2	0.2	0.4	0.6
Attributable EBITDA	<u>\$ 0.6</u>	<u>\$ 0.1</u>	<u>\$ 0.8</u>	<u>\$ 0.5</u>

- (5) Investment expense during the three months ended June 30, 2026 includes unrealized losses on the

Company's investment in Hycroft of \$1.5 million, partially offset by interest income of \$(1.0) million. Investment income during the three months ended June 30, 2025 included interest income of \$(1.7) million, partially offset by unrealized losses on the Company's investments in Hycroft of \$0.3 million.

Investment income during the six months ended June 30, 2026 includes realized and unrealized gains on the Company's investments in Hycroft of \$(16.5) million and interest income of \$(1.3) million. Investment income during the six months ended June 30, 2025 included interest income of \$(4.6) million and unrealized gains on the Company's investments in Hycroft of \$(2.5) million.

- (6) Other expense during the three months ended June 30, 2026 includes the increase in the fair value of the bifurcated embedded derivative in the New Exchangeable Notes of \$41.3 million, the loss on extinguishment of the New Exchangeable Notes of \$33.0 million, the loss on extinguishment of the Odeon Notes due 2027 of \$30.1 million, the increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$9.8 million, and net periodic pension cost of \$0.5 million, partially offset by foreign currency transaction gains of \$(0.4) million. Other income during the three months ended June 30, 2025 included foreign currency transaction gains of \$(23.9) million, partially offset by an increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$3.9 million and \$0.3 million of net periodic pension cost.

Other expense during the six months ended June 30, 2026 includes the loss on extinguishment of the New Exchangeable Notes of \$33.0 million, the loss on extinguishment of the Odeon Notes due 2027 of \$30.1 million, foreign currency transaction losses of \$8.6 million, the increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$2.7 million, net periodic pension cost of \$1.0 million and debt modification third party fees of \$0.3 million, partially offset by the decrease in the fair value of the bifurcated embedded derivative in the New Exchangeable Notes of \$(11.1) million. Other income during the six months ended June 30, 2025 included a decrease in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$(41.2) million and foreign currency transaction gains of \$(36.9) million, partially offset by \$0.6 million of net periodic pension cost.

- (7) Merger, acquisition and other costs are excluded as they are non-operating in nature.

- (8) Non-cash expense included in general and administrative: other.

NOTE 10—LOSS PER SHARE

Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted loss per share includes the effects of unvested RSUs with a service condition only, unvested contingently issuable PSUs that have service and performance conditions, and shares issuable upon exchange of the Existing Exchangeable Notes, if dilutive. Diluted loss per share is computed using the treasury stock method for the RSUs and PSUs and the if-converted method for the Existing Exchangeable Notes.

The following table sets forth the computation of basic and diluted loss per common share:

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Numerator:				
Net loss for basic and diluted loss per share	\$ (11.4)	\$ (4.7)	\$ (128.5)	\$ (206.8)
Denominator (shares in thousands):				
Weighted average shares for basic and diluted loss per common share	722,015	433,144	631,343	432,064
Basic and diluted loss per common share	<u>\$ (0.02)</u>	<u>\$ (0.01)</u>	<u>\$ (0.20)</u>	<u>\$ (0.48)</u>

Vested RSUs and PSUs have dividend rights identical to the Company's Common Stock and are treated as outstanding shares for purposes of computing basic and diluted loss per share.

Included in the computation of basic loss per share are 766,346 contingently issuable RSUs whose issuance conditions were satisfied when the grantee attained retirement eligibility. These contingently issuable RSUs will not be

issued until their vesting dates. For both the three and six months ended June 30, 2026, 1,981,745 unvested RSUs were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive. For both the three and six months ended June 30, 2025, 4,560,303 unvested RSUs were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Unvested PSUs are subject to performance conditions and are included in diluted loss per share, if dilutive, based on the number of shares, if any, that would be issuable under the terms of the award agreements if the end of the reporting period were the end of the contingency period. For both the three and six months ended June 30, 2026, 3,557,261 unvested PSUs at certain performance targets were excluded from the computation of diluted loss per share as they would not be issuable if the end of the reporting period were the end of the contingency period or as their effect would have been anti-dilutive. For both the three and six months ended June 30, 2025, 2,201,477 unvested PSUs at certain performance targets were excluded from the computation of diluted loss per share as they would not be issuable if the end of the reporting period were the end of the contingency period or as their effect would have been anti-dilutive.

The Company excluded approximately 23.1 million shares issuable upon exchange of the Existing Exchangeable Notes from the computation of diluted loss per share for both the three and six months ended June 30, 2026 as their effect would have been anti-dilutive. The Company excluded approximately 88.7 million shares issuable upon exchange of the Existing Exchangeable Notes from the computation of diluted loss per share for both the three and six months ended June 30, 2025 as their effect would have been anti-dilutive.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

In addition to historical information, this Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “forecast,” “estimate,” “project,” “intend,” “plan,” “expect,” “should,” “believe” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions and speak only as of the date on which it is made. Examples of forward-looking statements include statements we make regarding future attendance levels, revenues and our liquidity. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors, including those discussed in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the following:

- the risks and uncertainties relating to the sufficiency of our existing cash and cash equivalents and available borrowing capacity to fund operations and satisfy obligations including cash outflows for planned capital expenditures currently and through the next twelve months. Based on our current cost structure, in order to achieve annual net positive cash flows from operating activities, revenues will need to be at least in line with pre-COVID-19 revenues. However, there remain significant risks that may negatively impact revenues, costs, and attendance levels, including changes to movie studios release schedules (including as a result of production delays and delays to the release of movies caused by labor stoppages) and direct to streaming or other changing movie studio practices. If we are unable to achieve increased levels of attendance and revenues, we will be required to obtain additional liquidity. If such additional liquidity is not obtained or is insufficient, we likely would seek an in-court or out-of-court restructuring of our liabilities, and in the event of such future liquidation or bankruptcy proceeding, holders of our Common Stock and other securities would likely suffer a total loss of their investment;
- the risks and uncertainties relating to the 2025 Refinancing Transactions and 2024 Refinancing Transactions (each defined herein), including, but not limited to, (i) the potential for additional future dilution of our Common Stock as a result of issuance of shares underlying our Existing Exchangeable Notes, (ii) the possibility that the extension of certain debt maturities will not provide enough time for attendance and revenues to increase to sufficient levels and generate net positive cash flows to overcome liquidity concerns, and (iii) the impact on the market price of our Common Stock and our capital structure

of any litigation or claims of default that might arise in connection with the 2025 Refinancing Transactions or 2024 Refinancing Transactions;

- changing practices of distributors, which accelerated during the COVID-19 pandemic, including increased use of alternative film delivery methods including premium video on demand, streaming platforms, shrinking exclusive theatrical release windows or release of movies to theatrical exhibition and streaming platforms on the same date, the theatrical release of fewer movies due to industry consolidation or other reasons, or transitioning to other forms of entertainment;
- the impact of changing movie-going behavior of consumers;
- the risk that the North American and international box office in the near term will not recover sufficiently, resulting in continued cash burn and the need to seek additional financing, which may not be available at favorable terms, or at all;
- risks and uncertainties relating to our significant indebtedness, including our borrowings and our ability to meet our debt covenants;
- the dilution caused by recent and potential future sales of our Common Stock and future potential share issuances to repay, refinance, redeem or repurchase indebtedness (including expenses, accrued interest and premium, if any);
- risks relating to motion picture production, promotion, marketing, and performance, including labor stoppages affecting the production, supply and release schedule of theatrical motion picture content and choice of distributors to release fewer feature-length films as a result of the additional financial burden imposed by tariffs on motion picture production;
- the potential impact on our business resulting from consolidation among, or structural changes to, movie studios, distribution companies, or producers of other third-party media, including the uncertainty created when any such transaction is the subject of pending regulatory review, judicial proceedings, or injunctive relief, the outcome of which may materially affect the structure and dynamics of the markets in which we operate and the production and release of theatrical motion pictures;
- the use of artificial intelligence (“AI”) technology in the filmmaking process and audience acceptance of movies made utilizing AI technology;
- the seasonality of our revenue and working capital, which are dependent upon the timing of motion picture releases by distributors, such releases being seasonal and resulting in higher attendance and revenues generally during the summer months and holiday seasons, and higher working capital requirements during the other periods such as the first quarter;
- intense competition in the geographic areas in which we operate among exhibitors, streaming platforms, or from other forms of entertainment;
- certain covenants in the agreements that govern our indebtedness that limit or restrict our ability to take advantage of certain business opportunities, pay dividends, incur additional debt, pre-pay debt, and also to refinance debt and to do so at favorable terms, and such covenants that impose additional administrative and operational burdens on our business;
- risks relating to impairment losses, including with respect to goodwill and other intangibles, and theatre and other closure charges;
- general and international economic, political, regulatory, social and financial market conditions, including potential economic recession, inflation, rising interest rates, the financial stability of the banking industry, and other risks that may negatively impact discretionary income and our revenues and attendance levels;
- our lack of control over distributors of films;

- limitations on the availability of capital or poor financial results may prevent us from deploying strategic initiatives;
- an issuance of preferred stock could dilute the voting power of the common stockholders and adversely affect the market value of our outstanding Common Stock;
- limitations on the authorized number of Common Stock shares could in the future prevent us from raising additional capital through sales of Common Stock;
- our ability to achieve expected synergies, benefits and performance from our strategic initiatives;
- our ability to refinance our indebtedness on terms favorable to us or at all;
- our ability to optimize our theatre circuit through new construction, the transformation of our existing theatres, and strategically closing underperforming theatres may be subject to delay and unanticipated costs;
- failures, unavailability or security breaches of our information systems, including due to cybersecurity incidents;
- our ability to utilize interest expense deductions will be limited annually due to Section 163(j) of the Internal Revenue Code of 1986, as amended, as amended by the One Big Beautiful Bill Act of 2025;
- our ability to recognize interest deduction carryforwards, net operating loss carryforwards and other tax attributes to reduce our future tax liability;
- our ability to recognize certain international deferred tax assets which currently do not have a valuation allowance recorded;
- review by antitrust authorities in connection with acquisition opportunities;
- risks relating to the incurrence of legal liability;
- dependence on key personnel for current and future performance and our ability to attract and retain senior executives and other key personnel, including in connection with any future acquisitions;
- increased costs in order to comply or resulting from a failure to comply with governmental regulation, including the General Data Protection Regulation and all other current and pending privacy and data regulations in the jurisdictions where we have operations;
- supply chain disruptions may negatively impact our operating results;
- the availability and/or cost of energy;
- the market price and trading volume of our shares of Common Stock has been and may continue to be volatile, and purchasers of our securities could incur substantial losses;
- future offerings of debt, which would be senior to our Common Stock for purposes of distributions or upon liquidation, could adversely affect the market price of our Common Stock;
- the potential for political, social, or economic unrest, terrorism, hostilities, cyber-attacks or war, including the conflict between Russia and Ukraine, military actions in and around Iran, and other international conflicts;
- the potential impact of financial and economic sanctions on the regional and global economy, or widespread health emergencies, such as pandemics or epidemics, causing people to avoid our theatres or other public places where large crowds are in attendance;

[Table of Contents](#)

- anti-takeover protections in our Fourth Amended and Restated Certificate of Incorporation and our Fourth Amended and Restated Bylaws may discourage or prevent a takeover of our Company, even if an acquisition would be beneficial to our stockholders; and
- other risks and uncertainties referenced from time to time in filings with the Securities and Exchange Commission (“SEC”).

This list of factors that may affect future performance and the accuracy of forward-looking statements is illustrative but not exhaustive. In addition, new risks and uncertainties may arise from time to time. Accordingly, all forward-looking statements should be evaluated with an understanding of their inherent uncertainty and we caution accordingly against relying on forward-looking statements.

Except as required by law, we assume no obligation to publicly update or revise these forward-looking statements for any reason. Actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Readers are urged to consider these factors carefully in evaluating the forward-looking statements. For further information about these and other risks and uncertainties as well as strategic initiatives, see “Item 1A. Risk Factors” of this Form 10-Q, “Item 1. Business” in our Annual Report on Form 10-K for the year ended December 31, 2025, and our other public filings.

All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements included herein are made only as of the date of this Quarterly Report on Form 10-Q, and we do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Overview

AMC is the world’s largest theatrical exhibition company and an industry leader in innovation and operational excellence. As of June 30, 2026, we operated theatres in 11 countries, including the United States, and various countries throughout Europe.

Our theatrical exhibition revenues are generated primarily from box office admissions and food and beverage sales. The balance of our revenues is generated from ancillary sources, including online ticketing fees, on-screen advertising, income from gift card and exchange ticket sales, rental of theatre auditoriums, retail popcorn and merchandise sales, fees earned from our customer loyalty programs, and theatrical distribution. As of June 30, 2026, we owned, operated or had interests in 845 theatres and 9,530 screens.

Box Office Admissions and Film Content

Box office admissions are our largest source of revenue. We predominantly license theatrical films from distributors owned by major film production companies and from independent distributors on a film-by-film and theatre-by-theatre basis. Film exhibition costs are based on a share of admissions revenues and are accrued based on estimates of the final settlement pursuant to our film licenses. These licenses typically state that rental fees are based on the box office performance of each film, though in certain circumstances and less frequently, our rental fees are based on a mutually agreed settlement rate that is fixed. In some European territories, film rental fees are established on a weekly basis and some licenses use a per capita agreement instead of a revenue share, paying a flat amount per ticket.

Our revenues attributable to individual distributors may vary significantly from year to year depending upon the commercial success of each distributor’s films in any given year. Our results of operations may vary significantly from quarter to quarter and from year to year based on the timing and popularity of film releases.

Movie Screens

The following table provides detail with respect to Premium Large Format (“PLF”) screens (IMAX®, Dolby Cinema™, SCREENX, 4DX, in-house), XL screens, 3D enabled screens, premium seating, and our enhanced food and beverage offerings as deployed throughout our circuit as of June 30, 2026 and June 30, 2025:

Format	U.S. Markets		International Markets		Consolidated	
	As of June 30,		As of June 30,		As of June 30,	
	2026	2025	2026	2025	2026	2025
Number of theatres:						
IMAX®	186	182	39	35	225	217
Dolby Cinema™ theatres	175	167	7	7	182	174
In-house PLF	74	63	80	79	154	142
Dine-in	22	48	3	3	25	51
Premium seating	368	366	90	88	458	454
XL screens	58	10	74	72	132	82
SCREENX	5	—	6	6	11	6
4DX	3	—	—	—	3	—
3D enabled	514	528	247	262	761	790
Number of screens:						
IMAX®	187	183	39	35	226	218
Dolby Cinema™ theatres	175	167	7	7	182	174
In-house PLF	78	67	83	82	161	149
Dine-in	226	666	13	13	239	679
Premium seating	3,648	3,641	651	618	4,299	4,259
XL screens	102	19	91	85	193	104
SCREENX	5	—	6	6	11	6
4DX	3	—	—	—	3	—
3D enabled	2,756	2,827	913	1,042	3,669	3,869

Loyalty Programs and Other Marketing

As of June 30, 2026, we had a combined total of approximately 40.7 million member households enrolled in our AMC Stubs® A-List, AMC Stubs Premiere™, AMC Stubs Premiere *GO!*, and AMC Stubs Insider™ programs (collectively, “AMC Stubs”). During the six months ended June 30, 2026, our AMC Stubs members represented approximately 51.6% of AMC U.S. markets attendance.

We currently have approximately 20.8 million total members in our various International loyalty & subscription programs.

See “Item 1. Business” in our Annual Report on Form 10-K for the year ended December 31, 2025 for additional discussion and information of our screens, seating concepts, amenities, loyalty programs and other marketing initiatives.

Holders of Shares

As of June 30, 2026, there were 892,604,638 shares of our Common Stock outstanding. Of those outstanding shares, approximately 2.2 million shares (or 0.25%) were held by 13,720 registered holders with our transfer agent and approximately 890.4 million (or 99.75%) were held by Cede & Co on behalf of the Depository Trust & Clearing Corporation, commonly referred to as held in “street name” for beneficial holders owning shares through bank or brokerage accounts.

Critical Accounting Estimates

For a discussion of our critical accounting policies and the means by which we develop estimates, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025.

Significant Events—For the Six Months Ended June 30, 2026

Odeon Credit Agreement. On April 17, 2026, Odeon Finco, a wholly-owned direct subsidiary of OCGL and an indirect subsidiary of Holdings, entered into the Odeon Credit Agreement, by and among Odeon Finco, as borrower, OCGL, as the company, the lenders party thereto and U.S. Bank Trust Company, National Association, as administrative agent and security agent, pursuant to which Odeon Finco borrowed \$425.0 million of Odeon Term Loans due 2031. The Odeon Term Loans due 2031 bear interest at a fixed 10.50% interest rate and are subject to amortization of principal, payable in quarterly installments on the fifteenth day of each April, July, October, and January (commencing July 15, 2026), equal to 1.00% per annum.

The proceeds from the Odeon Term Loans due 2031 and approximately \$38.2 million of cash from the balance sheet were used to fund the Odeon Notes Redemption of Odeon Finco’s outstanding Odeon Notes due 2027 and to pay related fees, costs, premiums and expenses, including approximately \$23.5 million of interest due on the Odeon Notes due 2027. In connection with the Odeon Notes Redemption, the Odeon Notes due 2027 have been delisted from the Official List of The International Stock Exchange. We treated the Odeon Notes Redemption as an extinguishment of debt and recorded a \$30.1 million loss on extinguishment. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

New Exchangeable Notes Voluntary Exchange. On May 4 and May 11, 2026, the Exchanging Noteholders delivered Notices of Voluntary Exchange to Muvico and GLAS Trust Company LLC, as exchange agent, to exchange all \$155,845,562 aggregate principal amount of New Exchangeable Notes outstanding for shares of Common Stock, pursuant to the terms of the Indenture. The Company settled the Exchange by issuing an aggregate of 142,102,295 shares of Common Stock to the Exchanging Noteholders (including shares issued in respect of the Exchange Adjustment Consideration (as defined in the Indenture) and accrued and unpaid interest). We treated the Exchange as an extinguishment of the New Exchangeable Notes (including the bifurcated embedded derivative liability for the embedded conversion features) and recorded a loss on extinguishment of \$33.0 million. We adjusted the bifurcated embedded derivative liability to fair value immediately prior to the Exchange and recorded \$41.3 million of expense during the three months ended June 30, 2026. During the six months ended June 30, 2026, we recorded \$(11.1) million of other income related to the decrease in the fair value of the bifurcated embedded derivative liability. As a result of the Exchange, all remaining New Exchangeable Notes were cancelled in accordance with the Indenture.

Share Issuances. In June 2026, we entered into the Purchase Agreement with the Investors for the sale of 95,250,000 shares of Common Stock in the Offering, at a purchase price of \$2.10 per share. The Offering closed on June 24, 2026.

In connection with the Offering, we entered into the Placement Agency Agreement with the Placement Agent, as exclusive placement agent in connection with the Offering. As compensation to the Placement Agent, the Company will pay the Placement Agent a cash fee of 5.5% of the aggregate gross proceeds raised in the Offering and will reimburse certain expenses. We will use the proceeds from the Offering to redeem the Senior Subordinated Notes due 2027, pay related fees, costs, premiums and expenses associated therewith and for general corporate purposes, which may include the repayment of other debt, the strengthening of our cash reserves and investments to enhance the moviegoing experience at our theatres.

[Table of Contents](#)

The below table summarizes activity during the six months ended June 30, 2026 related to the Offering:

(In millions)	Six Months Ended June 30, 2026
Shares issued direct offering	95.3
Direct offering gross proceeds	\$ 200.0
Placement fees paid	\$ 11.0
Other third-party issuance costs incurred	\$ 0.2
Other third-party issuance costs paid	\$ 0.2

During the six months ended June 30, 2026, we issued shares through an “at-the-market offering”. The below table summarizes the activity of the “at-the-market” offering.

(In millions)	Six Months Ended June 30, 2026
Shares issued through at-the-market offering	105.3
At-the-market offering gross proceeds	\$ 150.0
Sales agent fees paid	\$ 3.0
Other third-party issuance costs incurred	\$ 1.9
Other third-party issuance costs paid	\$ 1.2

See Note 6—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q for further information on the share issuances.

Hycroft. On February 5, 2026, the Company exercised its remaining warrants to purchase 1,000,824 common shares of Hycroft on a cashless basis and received 765,440 common shares of Hycroft. During the six months ended June 30, 2026, we sold 700,000 common shares of Hycroft for \$29.7 million. As of June 30, 2026, we held 129,478 remaining common shares of Hycroft. We recorded realized and unrealized gains related to our investments in Hycroft in investment income of \$(16.5) million during the six months ended June 30, 2026.

Significant Events—For the Six Months Ended June 30, 2025

NCM ESA Amendment. On April 17, 2025, NCM entered into the Amended ESA with the Company. The term of the Amended ESA has been extended by five years through February 13, 2042. The Amended ESA was treated as a contract modification pursuant to *ASC 606 – Revenue from Contracts with Customers*. Accordingly, we have allocated the additional consideration from the contract modification to the exhibitor services agreement contract liability and updated the discount rate used to account for the significant financing component to 16.12%. Prior to the contract modification, the weighted average discount rate used to account for the significant financing component was approximately 7.5%. The contract liability will be reclassified to other theatre revenue over the new term of the Amended ESA as the remaining performance obligations are satisfied. Concurrently with entering into the Amended ESA, NCM and the Company reached an agreement to, among other things, dismiss with prejudice the ongoing litigation between the parties.

Share Issuances. During the six months ended June 30, 2025, we were paid \$108.7 million as initial gross cash proceeds associated with the establishment of forward positions for 30.0 million shares of Common Stock.

Additionally, during the six months ended June 30, 2025, we issued shares through an “at-the-market offering.” The below table summarizes the activity of the “at-the-market” offering during the six months ended June 30, 2025:

(In millions)	June 30, 2025
Shares issued through at-the-market offering	17.1
At-the-market offering gross proceeds	\$ 63.0
Sales agent fees paid	\$ 0.6
Other third-party issuance costs incurred	\$ 0.3
Other third-party issuance costs paid	\$ 1.5

See Note 6—Stockholders’ Deficit in the Notes to the Condensed Consolidated Financial Statements in Part I,

[Table of Contents](#)

Item 1 of this Form 10-Q for further information on the share issuances.

Operating Results

The following table sets forth our consolidated revenues, operating costs and expenses:

(In millions)	Three Months Ended			Six Months Ended		
	June 30, 2026	June 30, 2025	% Change	June 30, 2026	June 30, 2025	% Change
Revenues						
Admissions	\$ 863.1	\$ 762.6	13.2 %	\$ 1,441.5	\$ 1,236.1	16.6 %
Food and beverage	576.1	499.6	15.3 %	923.4	783.0	17.9 %
Other theatre	157.5	135.7	16.1 %	277.2	241.3	14.9 %
Total revenues	1,596.7	1,397.9	14.2 %	2,642.1	2,260.4	16.9 %
Operating Costs and Expenses						
Film exhibition costs	440.3	392.1	12.3 %	695.9	596.9	16.6 %
Food and beverage costs	107.7	96.1	12.1 %	174.1	153.3	13.6 %
Operating expense, excluding depreciation and amortization below	458.4	458.4	0.0 %	865.7	851.6	1.7 %
Rent	223.8	222.6	0.5 %	447.9	440.7	1.6 %
General and administrative:						
Merger, acquisition and other costs	0.3	0.1	* %	1.4	3.1	(54.8)%
Other, excluding depreciation and amortization below	52.0	58.2	(10.7)%	112.9	114.2	(1.1)%
Depreciation and amortization	76.1	77.8	(2.2)%	151.8	153.9	(1.4)%
Operating costs and expenses	1,358.6	1,305.3	4.1 %	2,449.7	2,313.7	5.9 %
Operating income (loss)	238.1	92.6	* %	192.4	(53.3)	* %
Other expense, net:						
Other expense (income)	109.6	(32.1)	* %	57.2	(90.9)	* %
Interest expense:						
Corporate borrowings	115.9	109.6	5.7 %	235.8	218.6	7.9 %
Finance lease obligations	1.7	1.4	21.4 %	3.2	2.6	23.1 %
Non-cash NCM exhibitor service agreement	18.4	18.6	(1.1)%	36.9	27.5	34.2 %
Investment expense (income)	0.5	(1.4)	* %	(17.8)	(7.1)	* %
Total other expense, net	246.1	96.1	* %	315.3	150.7	* %
Loss before income taxes	(8.0)	(3.5)	* %	(122.9)	(204.0)	(39.8)%
Income tax provision	3.4	1.2	* %	5.6	2.8	100.0 %
Net loss	\$ (11.4)	\$ (4.7)	* %	\$ (128.5)	\$ (206.8)	(37.9)%

* Percentage change in excess of 100%

Operating Data:	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Screen acquisitions	—	25	8	25
Screen dispositions	66	21	100	101
Screen construction (closures), net	(11)	(12)	(18)	(5)
Average screens (1)	9,249	9,402	9,280	9,416
Number of screens operated	9,530	9,717	9,530	9,717
Number of theatres operated	845	864	845	864
Screens per theatre	11.3	11.2	11.3	11.2
Attendance (in thousands) (1)	71,290	62,807	118,912	104,710

(1) Includes consolidated theatres only and excludes screens offline due to construction.

Segment Operating Results

The following table sets forth our revenues, operating costs and expenses by reportable segment:

(In millions)	U.S. Markets		International Markets		Consolidated	
	Three Months Ended		Three Months Ended		Three Months Ended	
	June 30,		June 30,		June 30,	
	2026	2025	2026	2025	2026	2025
Revenues						
Admissions	\$ 667.1	\$ 598.7	\$ 196.0	\$ 163.9	\$ 863.1	\$ 762.6
Food and beverage	470.0	411.4	106.1	88.2	576.1	499.6
Other theatre	121.5	104.1	36.0	31.6	157.5	135.7
Total revenues	1,258.6	1,114.2	338.1	283.7	1,596.7	1,397.9
Operating Costs and Expenses						
Film exhibition costs	362.0	325.6	78.3	66.5	440.3	392.1
Food and beverage costs	79.7	72.8	28.0	23.3	107.7	96.1
Operating expense, excluding depreciation and amortization below	345.2	343.1	113.2	115.3	458.4	458.4
Rent	161.6	162.7	62.2	59.9	223.8	222.6
General and administrative expense:						
Merger, acquisition and other costs	0.3	0.1	—	—	0.3	0.1
Other, excluding depreciation and amortization below	28.9	34.9	23.1	23.3	52.0	58.2
Depreciation and amortization	57.3	59.1	18.8	18.7	76.1	77.8
Operating costs and expenses	1,035.0	998.3	323.6	307.0	1,358.6	1,305.3
Operating income (loss)	223.6	115.9	14.5	(23.3)	238.1	92.6
Other expense (income), net:						
Other expense (income)	81.3	2.3	28.3	(34.4)	109.6	(32.1)
Interest expense:						
Corporate borrowings	102.9	94.4	13.0	15.2	115.9	109.6
Finance lease obligations	—	—	1.7	1.4	1.7	1.4
Non-cash NCM exhibitor service agreement	18.4	18.6	—	—	18.4	18.6
Investment expense (income)	0.8	(1.4)	(0.3)	—	0.5	(1.4)
Total other expense (income), net	203.4	113.9	42.7	(17.8)	246.1	96.1
Earnings (loss) before income taxes	20.2	2.0	(28.2)	(5.5)	(8.0)	(3.5)
Income tax provision	1.7	0.5	1.7	0.7	3.4	1.2
Net earnings (loss)	\$ 18.5	\$ 1.5	\$ (29.9)	\$ (6.2)	\$ (11.4)	\$ (4.7)

Segment Operating Data:	U.S. Markets		International Markets		Consolidated	
	Three Months Ended		Three Months Ended		Three Months Ended	
	June 30,		June 30,		June 30,	
	2026	2025	2026	2025	2026	2025
Screen acquisitions	—	16	—	9	—	25
Screen dispositions	57	8	9	13	66	21
Screen construction (closures), net	(11)	(12)	—	—	(11)	(12)
Average screens (1)	6,933	7,077	2,316	2,325	9,249	9,402
Number of screens operated	6,958	7,131	2,572	2,586	9,530	9,717
Number of theatres operated	524	540	321	324	845	864
Screens per theatre	13.3	13.2	8.0	8.0	11.3	11.2
Attendance (in thousands) (1)	52,529	46,889	18,761	15,918	71,290	62,807

(1) Includes consolidated theatres only and excludes screens offline due to construction.

[Table of Contents](#)

(In millions)	U.S. Markets		International Markets		Consolidated	
	Six Months Ended June 30,		Six Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025	2026	2025
Revenues						
Admissions	\$ 1,063.7	\$ 929.8	\$ 377.8	\$ 306.3	\$ 1,441.5	\$ 1,236.1
Food and beverage	729.0	628.6	194.4	154.4	923.4	783.0
Other theatre	206.7	172.8	70.5	68.5	277.2	241.3
Total revenues	1,999.4	1,731.2	642.7	529.2	2,642.1	2,260.4
Operating Costs and Expenses						
Film exhibition costs	548.6	476.8	147.3	120.1	695.9	596.9
Food and beverage costs	124.0	113.8	50.1	39.5	174.1	153.3
Operating expense, excluding depreciation and amortization below	637.3	631.5	228.4	220.1	865.7	851.6
Rent	324.0	325.3	123.9	115.4	447.9	440.7
General and administrative expense:						
Merger, acquisition and other costs	1.2	3.1	0.2	—	1.4	3.1
Other, excluding depreciation and amortization below	67.8	72.6	45.1	41.6	112.9	114.2
Depreciation and amortization	114.4	117.9	37.4	36.0	151.8	153.9
Operating costs and expenses	1,817.3	1,741.0	632.4	572.7	2,449.7	2,313.7
Operating income (loss)	182.1	(9.8)	10.3	(43.5)	192.4	(53.3)
Other expense (income), net:						
Other expense (income)	19.8	(43.1)	37.4	(47.8)	57.2	(90.9)
Interest expense:						
Corporate borrowings	207.3	188.2	28.5	30.4	235.8	218.6
Finance lease obligations	—	—	3.2	2.6	3.2	2.6
Non-cash NCM exhibitor service agreement	36.9	27.5	—	—	36.9	27.5
Investment income	(17.4)	(6.9)	(0.4)	(0.2)	(17.8)	(7.1)
Total other expense (income), net	246.6	165.7	68.7	(15.0)	315.3	150.7
Loss before income taxes	(64.5)	(175.5)	(58.4)	(28.5)	(122.9)	(204.0)
Income tax provision	2.2	1.4	3.4	1.4	5.6	2.8
Net loss	\$ (66.7)	\$ (176.9)	\$ (61.8)	\$ (29.9)	\$ (128.5)	\$ (206.8)

Segment Operating Data:	U.S. Markets		International Markets		Consolidated	
	Six Months Ended June 30,		Six Months Ended June 30,		Six Months Ended June 30,	
	2026	2025	2026	2025	2026	2025
Screen acquisitions	—	16	8	9	8	25
Screen dispositions	83	53	17	48	100	101
Screen construction openings (closures), net	(31)	(17)	13	12	(18)	(5)
Average screens (1)	6,963	7,090	2,317	2,326	9,280	9,416
Number of screens operated	6,958	7,131	2,572	2,586	9,530	9,717
Number of theatres operated	524	540	321	324	845	864
Screens per theatre	13.3	13.2	8.0	8.0	11.3	11.2
Attendance (in thousands) (1)	83,262	73,796	35,650	30,914	118,912	104,710

Segment Information

Our historical results of operations for the three and six months ended June 30, 2026 and June 30, 2025, reflect the results of operations for our two theatrical exhibition reportable segments, U.S. markets and International markets.

Results of Operations—For the Three Months ended June 30, 2026, Compared to the Three Months ended June 30, 2025

Condensed Consolidated Results of Operations

Revenues. Total revenues increased \$198.8 million, or 14.2%, during the three months ended June 30, 2026,

compared to the three months ended June 30, 2025. Admissions revenues increased \$100.5 million, or 13.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to an increase in attendance of 13.5% from 62.8 million patrons to 71.3 million patrons, partially offset by a 0.2% decrease in average ticket price. The decrease in average ticket price was primarily due to decreases in attendance for 3D and IMAX screens and increased frequency for our A-list subscription members, partially offset by increases in attendance for PLF and XL screens, increased ticket prices and increases in foreign currency translation rates. Attendance increased in U.S. and International markets due to the popularity of film product compared to the prior year.

Food and beverage revenues increased \$76.5 million, or 15.3%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 1.6% from \$7.95 to \$8.08 primarily due to an increase in average prices and the percentage of guests making transactions and increases in foreign currency translation rates, partially offset by lower units per transaction by guests.

Total other theatre revenues increased \$21.8 million, or 16.1%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance, the number of guests paying ticket fees and increases in the price of ticket fees, increases in advertising income and increases in foreign currency translation rates.

Operating costs and expenses. Operating costs and expenses increased \$53.3 million, or 4.1%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Film exhibition costs increased \$48.2 million, or 12.3%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in admissions revenue due to the factors discussed above, partially offset by the decrease in film exhibition cost percentage. As a percentage of admissions revenues, film exhibition costs were 51.0% for the three months ended June 30, 2026, compared to 51.4% for the three months ended June 30, 2025.

Food and beverage costs increased \$11.6 million, or 12.1%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above, partially offset by the decrease in food and beverage cost percentage. As a percentage of food and beverage revenues, food and beverage costs were 18.7% for the three months ended June 30, 2026, compared to 19.2% for the three months ended June 30, 2025.

Operating expense was unchanged during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. As a percentage of revenues, operating expense was 28.7% for the three months ended June 30, 2026, compared to 32.8% for the three months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense increased \$1.2 million, or 0.5%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 1.6%.

Merger, acquisition, and other costs. Merger, acquisition, and other costs were \$0.3 million during the three months ended June 30, 2026, compared to \$0.1 million during the three months ended June 30, 2025.

Other. Other general and administrative expense decreased \$6.2 million, or 10.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025 primarily due to decreases in legal expenses due to insurance recoveries and decreases in stock-based compensation expense, partially offset by the increase in foreign currency translation rates.

Depreciation and amortization. Depreciation and amortization decreased \$1.7 million, or 2.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025, partially offset by increases in foreign currency translation rates.

Other expense (income). Other expense of \$109.6 million during the three months ended June 30, 2026 was primarily due to \$41.3 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, \$33.0 million loss on extinguishment of the New Exchangeable Notes, \$30.1 million loss on extinguishment of the Odeon Notes due 2027 and \$9.8 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the Existing Exchangeable Notes, partially offset by \$(0.5) million in governmental assistance, \$(4.0) million in equity in earnings related to non-

consolidated entities and \$(0.4) million in foreign currency transaction gains. Other income of \$(32.1) million during the three months ended June 30, 2025 was primarily due to \$(23.9) million in foreign currency transaction gains, \$(10.3) million of governmental assistance, and \$(2.1) million of equity in earnings of non-consolidated entities, partially offset by \$3.9 million of expense related to the increase in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income).

Interest expense. Interest expense increased \$6.4 million to \$136.0 million for the three months ended June 30, 2026 compared to \$129.6 million during the three months ended June 30, 2025 primarily due to increased interest expense of \$31.3 million on the New 2029 Notes issued on July 24, 2025 and \$1.4 million on the New Exchangeable Notes issued on July 1, 2025, partially offset by declines in interest expense of \$11.4 million on the Existing 7.5% Notes due to redemptions of \$590.0 million aggregate principal amount on July 24, 2025, \$7.8 million on the Existing Exchangeable Notes issued on July 22, 2024 due to redemptions of \$337.4 million aggregate principal amount on July 24, 2025, \$2.4 million on the Muvico Term Loans due to lower interest rates, \$2.2 million related to the refinancing of the Odeon Notes due 2027, \$1.4 million on the Second Lien Notes due to redemptions of the remaining principal balances, \$0.7 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances, and \$0.5 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness.

Investment expense (income). Investment expense was \$0.5 million for the three months ended June 30, 2026, compared to investment income of \$(1.4) million for the three months ended June 30, 2025. Investment income in the current year includes \$1.5 million of unrealized losses on our investments in common shares in Hycroft, partially offset by interest income of \$(1.0) million. Investment income in the prior year includes interest income of \$(1.7) million, partially offset by \$0.3 million of unrealized losses on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our investments in Hycroft.

Income tax provision. The income tax provision was \$3.4 million and \$1.2 million for the three months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

Net loss. Net loss was \$11.4 million and \$4.7 million during the three months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the three months ended June 30, 2026 compared to net loss for the three months ended June 30, 2025 was negatively impacted by the decrease in other income, the increase in interest expense, the decrease in investment income, the increase in rent expense, the increase in income tax provision and the increase in foreign currency translation rates, partially offset by the increase in attendance as a result of the popularity of new film releases compared to the prior year, decreases in depreciation and amortization and decreases in general and administrative expenses.

Theatrical Exhibition—U.S. Markets

Revenues. Total revenues increased \$144.4 million, or 13.0%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Admissions revenues increased \$68.4 million, or 11.4%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to an increase in attendance of 12.0% from 46.9 million patrons to 52.5 million patrons, partially offset by a 0.5% decrease in average ticket price. The decrease in average ticket price was primarily due to decreases in attendance for 3D and IMAX screens and increased frequency for our A-list subscription members, partially offset by increases in attendance for PLF and XL screens and increased ticket prices. Attendance increased in U.S. markets due to the popularity of film product compared to the prior year.

Food and beverage revenues increased \$58.6 million, or 14.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 2.1% from \$8.77 to \$8.95 primarily due to an increase in average prices and the percentage of guests making transactions, partially offset by lower units per transaction by guests.

[Table of Contents](#)

Total other theatre revenues increased \$17.4 million, or 16.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance, the number of guests paying ticket fees and increases in the price of ticket fees, and increases in advertising income.

Operating costs and expenses. Operating costs and expenses increased \$36.7 million, or 3.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Film exhibition costs increased \$36.4 million, or 11.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in admissions revenue due to the factors discussed above, partially offset by the decrease in film exhibition cost percentage. As a percentage of admissions revenues, film exhibition costs were 54.3% for the three months ended June 30, 2026, compared to 54.4% for the three months ended June 30, 2025.

Food and beverage costs increased \$6.9 million, or 9.5%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above, partially offset by the decrease in food and beverage cost percentage. As a percentage of food and beverage revenues, food and beverage costs were 17.0% for the three months ended June 30, 2026, compared to 17.7% for the three months ended June 30, 2025.

Operating expense increased \$2.1 million, or 0.6%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. As a percentage of revenues, operating expense was 27.4% for the three months ended June 30, 2026, compared to 30.8% for the three months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense decreased \$1.1 million, or 0.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to a decrease in average screens of 2.0%.

Merger, acquisition, and other costs. Merger, acquisition, and other costs were \$0.3 million during the three months ended June 30, 2026, compared to \$0.1 million during the three months ended June 30, 2025.

Other. Other general and administrative expense decreased \$6.0 million, or 17.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to decreases in legal expenses due to insurance recoveries and decreases in stock-based compensation expense.

Depreciation and amortization. Depreciation and amortization decreased \$1.8 million, or 3.0%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025.

Other expense (income). Other expense of \$81.3 million during the three months ended June 30, 2026 was primarily due to \$41.3 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, \$33.0 million loss on extinguishment of the New Exchangeable Notes and \$9.8 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the Existing Exchangeable Notes, partially offset by \$(3.4) million in equity in earnings related to non-consolidated entities. Other expense of \$2.3 million during the three months ended June 30, 2025 was primarily due to \$3.9 million of expense related to the increase in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes, partially offset by \$(2.0) million in equity in earnings related to non-consolidated entities. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income).

Interest expense. Interest expense increased \$8.3 million to \$121.3 million for the three months ended June 30, 2026 compared to \$113.0 million during the three months ended June 30, 2025 primarily due to increased interest expense of \$31.3 million on the New 2029 Notes issued on July 24, 2025 and \$1.4 million on the New Exchangeable Notes issued on July 1, 2025, partially offset by declines in interest expense of \$11.4 million on the Existing 7.5% Notes due to redemptions of \$590.0 million aggregate principal amount on July 24, 2025, \$7.8 million on the Existing Exchangeable Notes issued on July 22, 2024 due to redemptions of \$337.4 million aggregate principal amount on July 24, 2025, \$2.4 million on the Muvico Term Loans due to lower interest rates, \$1.4 million on the Second Lien Notes due to redemptions of the remaining principal balances, \$0.7 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances, and \$0.5 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances. See Note 5—Corporate Borrowings and Finance Lease Liabilities in

[Table of Contents](#)

the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness.

Investment expense (income). Investment expense was \$0.8 million for the three months ended June 30, 2026, compared to investment income of \$(1.4) million for the three months ended June 30, 2025. Investment expense in the current year includes \$1.5 million of unrealized losses on our investments in common shares in Hycroft, partially offset by interest income of \$(0.7) million. Investment income in the prior year includes interest income of \$(1.7) million, partially offset by \$0.3 million of unrealized losses on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our investments in Hycroft.

Income tax provision. The income tax provision was \$1.7 million and \$0.5 million for the three months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

Net earnings. Net earnings were \$18.5 million and \$1.5 million during the three months ended June 30, 2026, and June 30, 2025, respectively. Net earnings during the three months ended June 30, 2026 compared to net earnings for the three months ended June 30, 2025 was positively impacted by the increase in attendance as a result of the popularity of new film releases compared to the prior year, decreases in rent expense, decreases in depreciation and amortization and decreases in general and administrative expenses, partially offset by the increase in other expense, the increase in interest expense, the decrease in investment income and the increase in income tax provision.

Theatrical Exhibition—International Markets

Revenues. Total revenues increased \$54.4 million, or 19.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Admissions revenues increased \$32.1 million, or 19.6%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to an increase in attendance of 17.9% from 15.9 million patrons to 18.8 million patrons and a 1.5% increase in average ticket price. The increase in average ticket price was primarily due to increases in foreign currency translation rates. Attendance increased in International markets due to the popularity of film product compared to the prior year.

Food and beverage revenues increased \$17.9 million, or 20.3%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 2.2% from \$5.54 to \$5.66 primarily due to increases in foreign currency translation rates.

Total other theatre revenues increased \$4.4 million, or 13.9%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance and increase in the number of guests paying ticket fees, increases in advertising income and increases in foreign currency translation rates.

Operating costs and expenses. Operating costs and expenses increased \$16.6 million, or 5.4%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. Film exhibition costs increased \$11.8 million, or 17.7%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to the increase in admissions revenues due to the factors discussed above, partially offset by the decrease in film exhibition cost percentage. As a percentage of admissions revenues, film exhibition costs were 39.9% for the three months ended June 30, 2026, compared to 40.6% for the three months ended June 30, 2025.

Food and beverage costs increased \$4.7 million, or 20.2%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above. As a percentage of food and beverage revenues, food and beverage costs were 26.4% for the three months ended June 30, 2026 and the three months ended June 30, 2025.

Operating expense decreased by \$2.1 million, or 1.8%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025. The decrease in operating expense was primarily due to lower salaries and utilities expenses, partially offset by the increase in foreign currency translation rates and the increase in attendance. As a percentage of revenues, operating expense was 33.5% for the three months ended June 30, 2026,

[Table of Contents](#)

compared to 40.6% for the three months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense increased \$2.3 million, or 3.8%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 0.4%.

Other. Other general and administrative expense decreased \$0.2 million, or 0.9%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025.

Depreciation and amortization. Depreciation and amortization increased \$0.1 million, or 0.5%, during the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025.

Other expense (income). Other expense of \$28.3 million during the three months ended June 30, 2026 was primarily due to \$30.1 million loss on extinguishment of the Odeon Notes due 2027, partially offset by \$(0.5) million in governmental assistance and \$(0.4) million in foreign currency transaction gains. Other income of \$(34.4) million during the three months ended June 30, 2025 was primarily due to \$(23.9) million in foreign currency transaction gains and \$(10.3) million of governmental assistance. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income).

Interest expense. Interest expense decreased \$1.9 million to \$14.7 million for the three months ended June 30, 2026 compared to \$16.6 million during the three months ended June 30, 2025 primarily due to a \$2.2 million decline related to the refinancing of the Odeon Notes due 2027. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness.

Investment income. Investment income was \$(0.3) million for the three months ended June 30, 2026, compared to investment income of \$0 million for the three months ended June 30, 2025. Investment income is comprised of interest income in the current period.

Income tax provision. The income tax provision was \$1.7 million and \$0.7 million for the three months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

Net loss. Net loss was \$29.9 million and \$6.2 million during the three months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the three months ended June 30, 2026 compared to net loss for the three months ended June 30, 2025 was negatively impacted by the decrease in other income, the increase in rent expense, the increase in depreciation and amortization, the increase in income tax provision and the increase in foreign currency translation rates, partially offset by the increase in attendance as a result of the popularity of new film releases compared to the prior year, the decrease in interest expense, and the decrease in general and administrative expenses and the increase in investment income.

Results of Operations—For the Six Months ended June 30, 2026, Compared to the Six Months ended June 30, 2025

Condensed Consolidated Results of Operations

Revenues. Total revenues increased \$381.7 million, or 16.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Admissions revenues increased \$205.4 million, or 16.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to an increase in attendance of 13.6% from 104.7 million patrons to 118.9 million patrons and a 2.7% increase in average ticket price. The increase in average ticket price was primarily due to increased ticket prices for all formats, increases in attendance for PLF and XL screens and increases in foreign currency translation rates, partially offset by decreases in attendance for 3D and IMAX screens and increased frequency for our A-list subscription members. Attendance increased in U.S. and International markets due to the popularity of film product compared to the prior year.

Food and beverage revenues increased \$140.4 million, or 17.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in attendance and increase in food and

beverage per patron. Food and beverage per patron increased 3.9% from \$7.48 to \$7.77 primarily due to an increase in average prices, the percentage of guests making transactions, and increases in foreign currency translation rates, partially offset by lower units per transaction by guests.

Total other theatre revenues increased \$35.9 million, or 14.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance, the number of guests paying ticket fees and increases in the price of ticket fees, increases in advertising income and increases in foreign currency translation rates, partially offset by decreases in income from expirations of package tickets and gift cards in our International markets. As a result of our Amended ESA, advertising income increased from the prior year by \$5.2 million due to an increase in discount rates related to the significant financing component of the Amended ESA, partially offset by lower amortization of deferred revenues due to an increase in the term of the Amended ESA. See Note 3—Revenue Recognition in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the Amended ESA.

Operating costs and expenses. Operating costs and expenses increased \$136.0 million, or 5.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Film exhibition costs increased \$99.0 million, or 16.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in admissions revenue due to the factors discussed above. As a percentage of admissions revenues, film exhibition costs were 48.3% for the six months ended June 30, 2026 and the six months ended June 30, 2025.

Food and beverage costs increased \$20.8 million, or 13.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above, partially offset by the decrease in food and beverage cost percentage. As a percentage of food and beverage revenues, food and beverage costs were 18.9% for the six months ended June 30, 2026, compared to 19.6% for the six months ended June 30, 2025.

Operating expense increased by \$14.1 million, or 1.7%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. As a percentage of revenues, operating expense was 32.8% for the six months ended June 30, 2026, compared to 37.7% for the six months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense increased \$7.2 million, or 1.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 1.4%.

Merger, acquisition, and other costs. Merger, acquisition, and other costs were \$1.4 million during the six months ended June 30, 2026, compared to \$3.1 million during the six months ended June 30, 2025. The prior year expense relates to severance costs in U.S. markets.

Other. Other general and administrative expense decreased \$1.3 million, or 1.1%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025 primarily due to decreases in legal expenses due to insurance recoveries and stock-based compensation expense, partially offset by increases in foreign currency translation rates.

Depreciation and amortization. Depreciation and amortization decreased \$2.1 million, or 1.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025, partially offset by increases in foreign currency translation rates.

Other expense (income). Other expense of \$57.2 million during the six months ended June 30, 2026 was primarily due to \$33.0 million loss on extinguishment of the New Exchangeable Notes, \$30.1 million loss on extinguishment of the Odeon Notes due 2027, \$8.6 million in foreign currency transaction losses and \$2.7 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the Existing Exchangeable Notes, partially offset by \$(11.1) million of income related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, \$(6.7) million in equity in earnings related to non-consolidated entities, and \$(0.5) million in governmental assistance. Other income of \$(90.9) million during the six months ended June 30, 2025 was primarily due to \$(41.2) million of income related to the

decrease in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes, \$(36.9) million in foreign currency transaction gains, \$(10.5) million of governmental assistance, and \$(2.9) million of equity in earnings of non-consolidated entities. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income).

Interest expense. Interest expense increased \$27.2 million to \$275.9 million for the six months ended June 30, 2026 compared to \$248.7 million during the six months ended June 30, 2025 primarily due to increased interest expense of \$62.2 million on the New 2029 Notes issued on July 24, 2025, \$9.4 million related to higher discount rates on the significant financing component of the Amended ESA and \$5.0 million on the New Exchangeable Notes issued on July 1, 2025, partially offset by declines in interest expense of \$22.8 million on the Existing 7.5% Notes due to redemptions of \$590.0 million aggregate principal amount on July 24, 2025, \$15.6 million on the Existing Exchangeable Notes issued on July 22, 2024 due to redemptions of \$337.4 million aggregate principal amount on July 24, 2025, \$4.5 million on the Muvico Term Loans due to lower interest rates, \$2.9 million on the Second Lien Notes due to redemptions of the remaining principal balances, \$1.8 million related to the refinancing of the Odeon Notes due 2027, \$1.3 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances, and \$1.2 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances. See Note 3—Revenue Recognition in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the Amended ESA and Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness.

Investment income. Investment income was \$(17.8) million for the six months ended June 30, 2026, compared to investment income of \$(7.1) million for the six months ended June 30, 2025. Investment income in the current year includes \$(16.5) million of realized and unrealized gains on our investments in common shares in Hycroft, and interest income of \$(1.3) million. Investment income in the prior year includes interest income of \$(4.6) million and \$(2.5) million of unrealized gains on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our investments in Hycroft.

Income tax provision. The income tax provision was \$5.6 million and \$2.8 million for the six months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

Net loss. Net loss was \$128.5 million and \$206.8 million during the six months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the six months ended June 30, 2026 compared to net loss for the six months ended June 30, 2025 was positively impacted by the increase in attendance as a result of the popularity of new film releases compared to the prior year, decreases in depreciation and amortization, decreases in general and administrative expenses and the increase in investment income, partially offset by the decrease in other income, the increase in interest expense, the increase in rent expense, the increase in income tax provision and the increase in foreign currency translation rates.

Theatrical Exhibition—U.S. Markets

Revenues. Total revenues increased \$268.2 million, or 15.5%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Admissions revenues increased \$133.9 million, or 14.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to an increase in attendance of 12.8% from 73.8 million patrons to 83.3 million patrons and a 1.4% increase in average ticket price. The increase in average ticket price was primarily due to increased ticket prices for all formats and increases in attendance for PLF and XL screens, partially offset by decreases in attendance for 3D and IMAX screens and increased frequency for our A-list subscription members. Attendance increased in U.S. markets due to the popularity of film product compared to the prior year.

Food and beverage revenues increased \$100.4 million, or 16.0%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 2.8% from \$8.52 to \$8.76 primarily due to an increase in average prices and the percentage of guests making transactions, partially offset by lower units per transaction by guests.

Total other theatre revenues increased \$33.9 million, or 19.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in income from ticket fees due to the increase in attendance, the number of guests paying ticket fees and increases in the price of ticket fees and increases in advertising income. As a result of our Amended ESA, advertising income increased from the prior year by \$5.2 million due to an increase in discount rates related to the significant financing component of the Amended ESA, partially offset by lower amortization of deferred revenues due to an increase in the term of the Amended ESA. See Note 3—Revenue Recognition in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the Amended ESA.

Operating costs and expenses. Operating costs and expenses increased \$76.3 million, or 4.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Film exhibition costs increased \$71.8 million, or 15.1%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in admissions revenue due to the factors discussed above and film rental terms. As a percentage of admissions revenues, film exhibition costs were 51.6% for the six months ended June 30, 2026, compared to 51.3% for the six months ended June 30, 2025.

Food and beverage costs increased \$10.2 million, or 9.0%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above, partially offset by a decrease in food and beverage cost as a percentage of food and beverage revenues. As a percentage of food and beverage revenues, food and beverage costs were 17.0% for the six months ended June 30, 2026, compared to 18.1% for the six months ended June 30, 2025.

Operating expense increased by \$5.8 million, or 0.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. As a percentage of revenues, operating expense was 31.9% for the six months ended June 30, 2026, compared to 36.5% for the six months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense decreased \$1.3 million, or 0.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to a decrease in average screens of 1.8%.

Merger, acquisition, and other costs. Merger, acquisition, and other costs were \$1.2 million during the six months ended June 30, 2026, compared to \$3.1 million during the six months ended June 30, 2025. The prior year expense relates to severance costs in U.S. markets.

Other. Other general and administrative expense decreased \$4.8 million, or 6.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to decreases in legal expenses due to insurance recoveries and stock-based compensation expense.

Depreciation and amortization. Depreciation and amortization decreased \$3.5 million, or 3.0%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025.

Other expense (income). Other expense of \$19.8 million during the six months ended June 30, 2026 was primarily due to \$33.0 million loss on extinguishment of the New Exchangeable Notes and \$2.7 million of expense related to the increase in fair value of the derivative liability for the embedded derivative features in the Existing Exchangeable Notes, partially offset by \$(11.1) million of income related to the increase in fair value of the derivative liability for the embedded derivative features in the New Exchangeable Notes, and \$(6.0) million in equity in earnings related to non-consolidated entities. Other income of \$(43.1) million during the six months ended June 30, 2025 was primarily due to \$(41.2) million of income related to the decrease in fair value of the derivative liability for the embedded conversion feature in the Existing Exchangeable Notes and \$(2.7) million of equity in earnings of non-consolidated entities. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income).

Interest expense. Interest expense increased \$28.5 million to \$244.2 million for the six months ended June 30, 2026 compared to \$215.7 million during the six months ended June 30, 2025 primarily due to increased interest expense of \$62.2 million on the New 2029 Notes issued on July 24, 2025, \$9.4 million related to higher discount rates on the significant financing component of the Amended ESA and \$5.0 million on the New Exchangeable Notes issued

on July 1, 2025, partially offset by declines in interest expense of \$22.8 million on the Existing 7.5% Notes due to redemptions of \$590.0 million aggregate principal amount on July 24, 2025, \$15.6 million on the Existing Exchangeable Notes issued on July 22, 2024 due to redemptions of \$337.4 million aggregate principal amount on July 24, 2025, \$4.5 million on the Muvico Term Loans due to lower interest rates, \$2.9 million on the Second Lien Notes due to redemptions of the remaining principal balances, \$1.3 million on the Senior Subordinated Notes due 2026 due to redemptions of the remaining principal balances, and \$1.2 million on the Senior Subordinated Notes due 2025 due to redemptions of the remaining principal balances. See Note 3—Revenue Recognition in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the Amended ESA and Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness.

Investment income. Investment income was \$(17.4) million for the six months ended June 30, 2026, compared to investment income of \$(6.9) million for the six months ended June 30, 2025. Investment income in the current year includes \$(16.5) million of realized and unrealized gains on our investments in common shares in Hycroft, and interest income of \$(0.9) million. Investment income in the prior year includes interest income of \$(4.4) million and \$(2.5) million of unrealized gains on our investments in common shares and warrants to purchase common shares in Hycroft. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our investments in Hycroft.

Income tax provision. The income tax provision was \$2.2 million and \$1.4 million for the six months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

Net loss. Net loss was \$66.7 million and \$176.9 million during the six months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the six months ended June 30, 2026 compared to net loss for the six months ended June 30, 2025 was positively impacted by the increase in attendance as a result of the popularity of new film releases compared to the prior year, the decrease in rent expense, decreases in depreciation and amortization, decreases in general and administrative expenses and the increase in investment income, partially offset by the decrease in other income, the increase in interest expense, and the increase in income tax provision.

Theatrical Exhibition—International Markets

Revenues. Total revenues increased \$113.5 million, or 21.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Admissions revenues increased \$71.5 million, or 23.3%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to an increase in attendance of 15.3% from 30.9 million patrons to 35.7 million patrons and a 7.0% increase in average ticket price. The increase in average ticket price was primarily due to increases in foreign currency translation rates. Attendance increased in International markets due to the popularity of film product compared to the prior year.

Food and beverage revenues increased \$40.0 million, or 25.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in attendance and increase in food and beverage per patron. Food and beverage per patron increased 9.2% from \$4.99 to \$5.45 primarily due to the increase in foreign currency translation rates, an increase in average prices and the percentage of guests making transactions, partially offset by lower units per transaction by guests.

Total other theatre revenues increased \$2.0 million, or 2.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to, increases in income from ticket fees due to the increase in attendance and the number of guests paying ticket fees, increases in advertising income and increases in foreign currency translation rates, partially offset by decreases in income from expirations of package tickets and gift cards in our International markets.

Operating costs and expenses. Operating costs and expenses increased \$59.7 million, or 10.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. Film exhibition costs increased \$27.2 million, or 22.6%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to the increase in admissions revenues due to the factors discussed above. As a percentage of admissions revenues, film exhibition costs were 39.0% for the six months ended June 30, 2026, compared to 39.2% for the six months ended June 30, 2025.

[Table of Contents](#)

Food and beverage costs increased \$10.6 million, or 26.8%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in food and beverage costs was primarily due to the increase in food and beverage revenues due to the factors discussed above. As a percentage of food and beverage revenues, food and beverage costs were 25.8% for the six months ended June 30, 2026, compared to 25.6% for the six months ended June 30, 2025.

Operating expense increased by \$8.3 million, or 3.8%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025. The increase in operating expense was primarily due to the increase in foreign currency translation rates and the increase in attendance. As a percentage of revenues, operating expense was 35.5% for the six months ended June 30, 2026, compared to 41.6% for the six months ended June 30, 2025. The decrease in operating expense as a percentage of revenues is primarily due to the operating leverage gained as attendance increases. Rent expense increased \$8.5 million, or 7.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by a decrease in average screens of 0.4%.

Merger, acquisition, and other costs. Merger, acquisition, and other costs were \$0.2 million during the six months ended June 30, 2026, compared to \$0 million during the six months ended June 30, 2025.

Other. Other general and administrative expense increased \$3.5 million, or 8.4%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025 primarily due to increases in foreign currency translation rates and increases in incentive bonus expense.

Depreciation and amortization. Depreciation and amortization increased \$1.4 million, or 3.9%, during the six months ended June 30, 2026, compared to the six months ended June 30, 2025, primarily due to increases in foreign currency translation rates, partially offset by theatre closures and lower depreciation expense on theatres impaired during the year ended December 31, 2025.

Other expense (income). Other expense of \$37.4 million during the six months ended June 30, 2026 was primarily due to \$30.1 million loss on extinguishment of the Odeon Notes due 2027 and \$8.6 million in foreign currency transaction losses, partially offset by governmental assistance of \$(0.5) million. Other income of \$(47.8) million during the six months ended June 30, 2025 was primarily due to \$(36.9) million in foreign currency transaction gains and \$(10.5) million of governmental assistance. See Note 1—Basis of Presentation in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about the components of other expense (income).

Interest expense. Interest expense decreased \$1.3 million to \$31.7 million for the six months ended June 30, 2026 compared to \$33.0 million during the six months ended June 30, 2025 due to the refinancing of the Odeon Notes due 2027, partially offset by higher interest costs on capital and financing lease obligations. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for additional information about our indebtedness.

Investment income. Investment income was \$(0.4) million for the six months ended June 30, 2026, compared to investment income of \$(0.2) million for the six months ended June 30, 2025. Investment income is comprised of interest income in the current and prior periods.

Income tax provision. The income tax provision was \$3.4 million and \$1.4 million for the six months ended June 30, 2026 and June 30, 2025, respectively. See Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

Net loss. Net loss was \$61.8 million and \$29.9 million during the six months ended June 30, 2026, and June 30, 2025, respectively. Net loss during the six months ended June 30, 2026 compared to net loss for the six months ended June 30, 2025 was negatively impacted by the decrease in other income, the increase in rent expense, increases in depreciation and amortization, increases in general and administrative expenses, the increase in income tax provision and the increase in foreign currency translation rates, partially offset by the increase in attendance as a result of the popularity of new film releases compared to the prior year, decreases in interest expense and the increase in investment income.

Adjusted EBITDA

We present Adjusted EBITDA as a supplemental measure of our performance. We define Adjusted EBITDA as net earnings (loss) plus (i) income tax provision (benefit), (ii) interest expense and (iii) depreciation and amortization, as further adjusted to eliminate the impact of certain items that we do not consider indicative of our ongoing operating performance and to include attributable EBITDA from equity investments in theatre operations in International markets. These further adjustments are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our definition of Adjusted EBITDA and adjustments made to net earnings (loss) to calculate it are broadly consistent with how Adjusted EBITDA is defined and calculated in our debt agreements.

During the first quarter of 2026, we changed our definition of Adjusted EBITDA to adjust for net periodic pension cost. Net periodic pension cost is a recurring expense that includes several components such as service cost, interest cost, expected return on plan assets, amortization of prior service cost, and amortization of actuarial gains/losses. Additionally, we also include infrequent gains and losses from benefit curtailments and settlements of pension obligations in net periodic pension cost. We no longer believe that net periodic pension cost should be included in Adjusted EBITDA as the pension plans are frozen, service cost is zero, and the remaining components are not indicative of ongoing operating performance as they are not driven by current operating decisions and largely depend on actuarial assumptions. While not the basis for this change, the revised definition further aligns our definition of Adjusted EBITDA with the definition used in our debt agreements. The adjustment for net periodic pension cost is included in the caption titled “other expense (income)” in the condensed consolidated statement of operations and in the reconciliation of net loss to Adjusted EBITDA further below. See the components of other expense (income) table in Note 1—Basis of Presentation for net periodic pension cost recorded in each period presented. All comparative period information for Adjusted EBITDA has been re-cast to conform with the current definition. The impact of this change on previously reported Adjusted EBITDA for the three and six months ended June 30, 2025 was an improvement of \$0.3 million and \$0.6 million, respectively.

The following tables set forth our Adjusted EBITDA by reportable operating segment and our reconciliation of Adjusted EBITDA:

Adjusted EBITDA (In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
U.S. markets	\$ 285.6	\$ 181.3	\$ 307.5	\$ 124.2
International markets	35.8	8.2	52.2	7.6
Total Adjusted EBITDA	\$ 321.4	\$ 189.5	\$ 359.7	\$ 131.8

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Net loss	\$ (11.4)	\$ (4.7)	\$ (128.5)	\$ (206.8)
Plus:				
Income tax provision (1)	3.4	1.2	5.6	2.8
Interest expense	136.0	129.6	275.9	248.7
Depreciation and amortization	76.1	77.8	151.8	153.9
Certain operating expense (2)	2.3	2.6	2.0	5.4
Equity in earnings of non-consolidated entities (3)	(4.0)	(2.1)	(6.7)	(2.9)
Attributable EBITDA (4)	0.6	0.1	0.8	0.5
Investment expense (income) (5)	0.5	(1.4)	(17.8)	(7.1)
Other expense (income) (6)	114.3	(19.7)	64.6	(77.5)
Merger, acquisition and other costs (7)	0.3	0.1	1.4	3.1
Stock-based compensation expense (8)	3.3	6.0	10.6	11.7
Adjusted EBITDA	\$ 321.4	\$ 189.5	\$ 359.7	\$ 131.8

- (1) For information regarding the income tax provision, see Note 7—Income Taxes in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q.

- (2) Amounts represent preopening expense related to temporarily closed screens under renovation, theatre and other closure expense for the permanent closure of screens, disposition of assets, and other non-operating gains or losses included in operating expenses. We have excluded these items as they are non-cash in nature or related to theatres that are not open.
- (3) Equity in earnings of non-consolidated entities during the three months ended June 30, 2026 primarily consisted of equity in earnings from AC JV of \$(3.3) million. Equity in earnings of non-consolidated entities during the three months ended June 30, 2025 primarily consisted of equity in earnings from AC JV of \$(1.8) million.

Equity in earnings of non-consolidated entities during the six months ended June 30, 2026 primarily consisted of equity in earnings from AC JV of \$(5.7) million. Equity in earnings of non-consolidated entities during the six months ended June 30, 2025 primarily consisted of equity in earnings from AC JV of \$(2.6) million.

- (4) Attributable EBITDA includes the EBITDA from equity investments in theatre operators in certain International markets. See below for a reconciliation of our equity in (earnings) of non-consolidated entities to attributable EBITDA. Because these equity investments are in theatre operators in regions where we hold a significant market share, we believe attributable EBITDA is more indicative of the performance of these equity investments and management uses this measure to monitor and evaluate these equity investments.

(In millions)	Three Months Ended		Six Months Ended	
	June 30, 2026	June 30, 2025	June 30, 2026	June 30, 2025
Equity in (earnings) of non-consolidated entities	\$ (4.0)	\$ (2.1)	\$ (6.7)	\$ (2.9)
Less:				
Equity in (earnings) of non-consolidated entities excluding International theatre joint ventures	(3.5)	(2.2)	(6.2)	(3.0)
Equity in earnings (loss) of International theatre joint ventures	0.5	(0.1)	0.5	(0.1)
Income tax benefit	—	(0.1)	—	(0.1)
Investment income	(0.1)	—	(0.1)	—
Interest expense	—	0.1	—	0.1
Depreciation and amortization	0.2	0.2	0.4	0.6
Attributable EBITDA	\$ 0.6	\$ 0.1	\$ 0.8	\$ 0.5

- (5) Investment expense during the three months ended June 30, 2026 includes unrealized losses on our investment in Hycroft of \$1.5 million, partially offset by interest income of \$(1.0) million. Investment income during the three months ended June 30, 2025 included interest income of \$(1.7) million, partially offset by unrealized losses on our investments in Hycroft of \$0.3 million.

Investment income during the six months ended June 30, 2026 includes realized and unrealized gains on our investments in Hycroft of \$(16.5) million and interest income of \$(1.3) million. Investment income during the six months ended June 30, 2025 included interest income of \$(4.6) million and unrealized gains on our investments in Hycroft of \$(2.5) million.

- (6) Other expense during the three months ended June 30, 2026 includes the increase in the fair value of the bifurcated embedded derivative in the New Exchangeable Notes of \$41.3 million, the loss on extinguishment of the New Exchangeable Notes of \$33.0 million, the loss on extinguishment of the Odeon Notes due 2027 of \$30.1 million, the increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$9.8 million and net periodic pension cost of \$0.5 million, partially offset by foreign currency transaction gains of \$(0.4) million. Other income during the three months ended June 30, 2025 included foreign currency transaction gains of \$(23.9) million, partially offset by an increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$3.9 million and \$0.3 million of net periodic pension cost.

Other expense during the six months ended June 30, 2026 includes the loss on extinguishment of the New Exchangeable Notes of \$33.0 million, the loss on extinguishment of the Odeon Notes due 2027 of \$30.1 million, foreign currency transaction losses of \$8.6 million, the increase in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$2.7 million, net periodic pension cost of \$1.0 million and debt modification third party fees of \$0.3 million, partially offset by the decrease in the fair value

of the bifurcated embedded derivative in the New Exchangeable Notes of \$(11.1) million. Other income during the six months ended June 30, 2025 included a decrease in the fair value of the bifurcated embedded derivative in the Existing Exchangeable Notes of \$(41.2) million and foreign currency transaction gains of \$(36.9) million, partially offset by \$0.6 million of net periodic pension cost.

(7) Merger, acquisition and other costs are excluded as they are non-operating in nature.

(8) Non-cash expense included in general and administrative: other.

Adjusted EBITDA is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to net earnings (loss) as an indicator of operating performance (as determined in accordance with U.S. GAAP). Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We have included Adjusted EBITDA because we believe it provides management and investors with additional information to measure our performance and estimate our value.

Adjusted EBITDA has important limitations as an analytical tool, and you should not consider it in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. For example, Adjusted EBITDA:

- does not reflect our capital expenditures, future requirements for capital expenditures or contractual commitments;
- does not reflect changes in, or cash requirements for, our working capital needs;
- does not reflect the significant interest expenses, or the cash requirements necessary to service interest or principal payments on our debt;
- excludes income tax payments that represent a reduction in cash available to us; and
- does not reflect any cash requirements for the assets being depreciated and amortized that may have to be replaced in the future.

During the three months ended June 30, 2026, Adjusted EBITDA in the U.S. markets was \$285.6 million compared to \$181.3 million during the three months ended June 30, 2025. The year-over-year increase was primarily driven by an increase in attendance due to the popularity of film releases compared to the prior year and an increase in food and beverage per patron, partially offset by lower average ticket price. During the three months ended June 30, 2026, Adjusted EBITDA in the International markets was \$35.8 million compared to \$8.2 million during the three months ended June 30, 2025. The year-over-year increase was primarily driven by an increase in attendance due to the popularity of film releases compared to the prior year and the increase in foreign currency translation rates, partially offset by lower amounts of governmental assistance. During the three months ended June 30, 2026, Adjusted EBITDA in the U.S. markets and International markets was \$321.4 million compared to \$189.5 million during the three months ended June 30, 2025, driven by the aforementioned factors impacting Adjusted EBITDA.

During the six months ended June 30, 2026, Adjusted EBITDA in the U.S. markets was \$307.5 million compared to \$124.2 million during the six months ended June 30, 2025. The year-over-year increase was primarily driven by an increase in attendance due to the popularity of film releases compared to the prior year, an increase in average ticket price and food and beverage per patron and an increase in advertising income in other revenues related to an increase in discount rates for the significant financing component of the Amended ESA. During the six months ended June 30, 2026, Adjusted EBITDA in the International markets was \$52.2 million compared to \$7.6 million during the six months ended June 30, 2025. The year-over-year increase was primarily driven by an increase in attendance due to the popularity of film releases compared to the prior year, an increase in average ticket price and food and beverage per patron and the increase in foreign currency translation rates, partially offset by lower amounts of governmental assistance and decreases in income from expirations of package tickets and gift cards. During the six months ended June 30, 2026, Adjusted EBITDA in the U.S. markets and International markets was \$359.7 million compared to \$131.8 million during the six months ended June 30, 2025, driven by the aforementioned factors impacting Adjusted EBITDA.

LIQUIDITY AND CAPITAL RESOURCES

Our consolidated revenues are primarily collected in cash, principally through admissions and food and beverage sales. We have an operating “float” which partially finances our operations and which generally permits us to maintain a smaller amount of working capital capacity. This float exists because admissions revenues are received in

[Table of Contents](#)

cash, while exhibition costs (primarily film rentals) are ordinarily paid to distributors from 14 to 49 days following receipt of admissions revenues. Film distributors generally release the films which they anticipate will be the most successful during the summer and year-end holiday seasons. Consequently, we typically generate higher revenues during such periods and experience higher working capital requirements following such periods.

We had working capital deficit (excluding restricted cash) as of June 30, 2026, and December 31, 2025 of \$(901.0) million and \$(1,090.6) million, respectively. As of June 30, 2026 and December 31, 2025, working capital included operating lease liabilities of \$560.4 million and \$560.0 million, respectively, and deferred revenues of \$452.6 million and \$465.5 million, respectively.

As of June 30, 2026, we had cash and cash equivalents of \$778.4 million.

During the six months ended June 30, 2026, we enhanced liquidity through equity issuances. See Note 6—Stockholders' Deficit in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

We expect, from time to time, to continue to seek to retire or purchase our outstanding debt through cash purchases and/or exchanges for equity or debt, in open-market purchases, privately negotiated transactions or otherwise. We continuously monitor the capital markets and our capital structure, and may, from time to time, seek to refinance, amend or otherwise restructure our outstanding debt on an opportunistic basis. Such repurchases, refinancings, amendments, restructurings or exchanges, if any, will be upon such terms and at such prices as we may determine, and will depend on prevailing market conditions, our liquidity requirements, the availability of authorized share capital, contractual restrictions and other factors. The amounts involved may be material and, to the extent equity is used, dilutive.

Odeon Credit Agreement

On April 17, 2026, Odeon Finco, a wholly-owned direct subsidiary of OCGL and an indirect subsidiary of Holdings, entered into the Odeon Credit Agreement, by and among Odeon Finco, as borrower, OCGL, as the company, the lenders party thereto and U.S. Bank Trust Company, National Association, as administrative agent and security agent, pursuant to which Odeon Finco borrowed \$425.0 million of Odeon Term Loans due 2031. The Odeon Term Loans due 2031 bear interest at a fixed 10.50% interest rate and are subject to amortization of principal, payable in quarterly installments on the fifteenth day of each April, July, October, and January (commencing July 15, 2026), equal to 1.00% per annum.

The proceeds from the Odeon Term Loans due 2031 and approximately \$38.2 million of cash from the balance sheet were used to fund the Odeon Notes Redemption of Odeon Finco's outstanding Odeon Notes due 2027 and to pay related fees, costs, premiums and expenses, including approximately \$23.5 million of interest due on the Odeon Notes due 2027. In connection with the Odeon Notes Redemption, the Odeon Notes due 2027 have been delisted from the Official List of The International Stock Exchange. See Note 5—Corporate Borrowings and Finance Lease Liabilities in the Notes to the Condensed Consolidated Financial Statements under Part I, Item 1 of this Form 10-Q for further information.

New Exchangeable Notes Voluntary Exchange

On May 4 and May 11, 2026, the Exchanging Noteholders delivered Notices of Voluntary Exchange to Muvico and GLAS Trust Company LLC, as exchange agent, to exchange all \$155,845,562 aggregate principal amount of New Exchangeable Notes outstanding for shares of Common Stock, pursuant to the terms of the Indenture. The Company settled the Exchange by issuing an aggregate of 142,102,295 shares of Common Stock to the Exchanging Noteholders (including shares issued in respect of the Exchange Adjustment Consideration (as defined in the Indenture) and \$0.9 million accrued and unpaid interest). As a result of the Exchange, all remaining New Exchangeable Notes were cancelled in accordance with the Indenture.

2027 Notes Redemption Notice

Concurrently with the completion of the Offering, on June 24, 2026, we delivered the Notice to holders of our \$125.5 million aggregate principal amount of Senior Subordinated Notes due 2027 to redeem the Senior Subordinated Notes due 2027 in full at a redemption price equal to 100.000% of the principal amount of the Senior Subordinated Notes due 2027, plus accrued and unpaid interest, if any, to July 24, 2026, the redemption date.

Liquidity Requirements

We believe our existing cash and cash equivalents, together with cash generated from operations, will be sufficient to fund our operations and satisfy our obligations currently and through the next twelve months. Our historical cash burn rates are not sustainable long-term. Based on our current cost structure, in order to achieve sustainable annual net positive cash flows from operating activities, we believe that revenues will need to be at least in line with pre-COVID-19 revenues. The Company has achieved net positive cash flows from operating activities for the six months ended June 30, 2026. Until such time as we are able to achieve sustainable annual net positive cash flows from operating activities, it is difficult to estimate our future cash burn rates and liquidity requirements. Depending on our assumptions regarding the timing and ability to achieve levels of revenue, the estimates of the required liquidity vary significantly.

There can be no assurance that the revenues, costs, attendance levels and other assumptions used to estimate our liquidity requirements and future cash burn rates will be correct, and our ability to be predictive is uncertain due to our limited ability to predict studio film release dates, the overall production and theatrical release levels and success of individual titles. Further, there can be no assurances that we will be successful in generating the additional liquidity necessary to meet our obligations beyond twelve months from the issuance of this Quarterly Report on terms acceptable to us or at all.

The following is a summary of our net cash flows for the six months ended June 30, 2026 and June 30, 2025:

(in millions)	June 30, 2026	June 30, 2025
Operating activities	\$ 106.9	\$ (231.6)
Investing activities	(59.6)	(95.6)
Financing activities	297.6	109.1

Cash Flows from Operating Activities

Net cash provided by (used in) operating activities improved by \$338.5 million primarily due to increases in attendance, increases in average ticket price, increases in food and beverage per patron, increases in advertising revenue, and an increase cash provided by working capital. The increase in cash provided by working capital was primarily driven by the float from film rental payments, which typically are paid to distributors 20 to 45 days following the receipt of admissions revenue. The box office in the second quarter of 2026 outperformed the box office in the second quarter of 2025.

Cash Flows from Investing Activities

Net cash used in investing activities decreased by \$36.0 million primarily due to proceeds from the sale of part of our investment in Hycroft and increases in proceeds from sales of long-term assets.

We fund the costs of constructing, maintaining and remodeling our theatres through existing cash balances, cash generated from operations, lease incentives, or capital raised, as necessary. We generally lease our theatres pursuant to long-term, non-cancelable operating leases, which may require the developer who owns the property, to help fund our construction costs by offering lease incentives. We estimate that our capital expenditures, net of lease incentives, will be approximately \$200.0 million to \$235.0 million for the year ending December 31, 2026 to maintain and enhance operations.

Cash Flows from Financing Activities

Net cash provided by financing activities increased by \$188.5 million primarily due to increased proceeds from equity issuances and decreases in cash used for principal payments of the Senior Subordinated Notes due 2025, partially offset by an increase in cash used to pay deferred financing costs.

Covenant Compliance

As of June 30, 2026, we believe that we were in full compliance with all agreements, including related covenants, governing our outstanding debt.

Formation of Unrestricted Subsidiaries

On July 22, 2024, Multi-Cinema, a Missouri corporation and a direct subsidiary of Holdings, assigned or transferred the net assets (“Theatre Net Assets”) of 175 theatres and transferred a 100% interest in certain intellectual property assets to its direct subsidiary Centertainment Development, LLC (“Centertainment”), and the Theatre Net Assets were in turn transferred to Centertainment’s direct wholly-owned subsidiary Muvico. Theatre Net Assets include lease contracts and theatre property, including furniture, fixtures, plant and equipment, and other working capital items associated directly with the theatre locations. At the same time, Muvico licensed the intellectual property back to Multi-Cinema for its continued use in the operation of its retained theatres and entered into a management agreement for Multi-Cinema to operate the theatres transferred to Muvico. Muvico and Centertainment (collectively, the “Muvico Group”) are unrestricted subsidiaries under the indenture governing Holdings’ 7.5% First Lien Senior Secured Notes (the “Existing 7.5% Notes”).

Unrestricted Subsidiaries’ Financial Information and Operating Metrics

Pursuant to the indenture governing Holdings’ Existing 7.5% Notes and the Muvico Credit Agreement governing Holdings’ and Muvico’s new term loans maturing in 2029 (the “Muvico Term Loans”), we are presenting the following financial information and operating metrics for the Muvico Group separately from Holdings and its restricted subsidiaries (the “Restricted Subsidiaries” and collectively with Holdings, the “AMC Group”). AMC Theatres of UK Limited, which is an unrestricted subsidiary under the indenture governing Holdings’ Existing 7.5% Notes, has been included with the Restricted Subsidiaries for the purposes of the following presentation of financial information and operating metrics (this subsidiary is individually immaterial). The financial information presented for AMC Group and Muvico Group is presented on a standalone basis with discrete identification of the assets, liabilities, revenues and expenses associated with the Theatre Net Assets that were transferred to Muvico. Intercompany transactions between entities within the AMC Group or within the Muvico Group have been eliminated. Certain entities within the AMC Group and within the Muvico Group are parties to intercompany management, licensing, and debt agreements with each other. These transactions are reflected discretely within the columnar presentation below and are properly eliminated upon consolidation. The financial information is also prepared using the historical cost carrying values of Holdings, the top parent entity.

Holdings and Muvico are co-borrowers and jointly and severally liable for the Muvico Term Loans. Pursuant to ASC 405-40, we have allocated fifty percent (50%) of the liabilities, interest expense and cash flows each to Muvico and Holdings, respectively. The basis of this allocation is the amount we expect each party to pay.

[Table of Contents](#)

(In millions)	Three Months Ended June 30, 2026			
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Eliminations (unaudited)	Consolidated (unaudited)
Revenues				
Admissions	\$ 600.5	\$ 262.6	\$ —	\$ 863.1
Food and beverage	430.9	145.2	—	576.1
Other theatre (3)	133.2	33.8	(9.5)	157.5
Total revenues	1,164.6	441.6	(9.5)	1,596.7
Operating costs and expenses				
Film exhibition costs	298.5	141.8	—	440.3
Food and beverage costs	84.1	23.6	—	107.7
Operating expense, excluding depreciation and amortization below	345.2	113.2	—	458.4
Rent	167.9	55.9	—	223.8
General and administrative:				
Merger, acquisition and other costs	0.3	—	—	0.3
Other, excluding depreciation and amortization below (3)	56.2	5.3	(9.5)	52.0
Depreciation and amortization	58.0	18.1	—	76.1
Operating costs and expenses	1,010.2	357.9	(9.5)	1,358.6
Operating income	154.4	83.7	—	238.1
Other expense, net:				
Other expense	25.4	84.2	—	109.6
Interest expense:				
Corporate borrowings	51.1	64.8	—	115.9
Finance lease obligations	1.7	—	—	1.7
Non-cash NCM exhibitor services agreement	18.4	—	—	18.4
Intercompany interest expense (income), net	(0.5)	0.5	—	—
Investment expense (income)	0.8	(0.3)	—	0.5
Total other expense, net	96.9	149.2	—	246.1
Earnings (loss) before income taxes	57.5	(65.5)	—	(8.0)
Income tax provision (2)	3.4	—	—	3.4
Net earnings (loss)	\$ 54.1	\$ (65.5)	\$ —	\$ (11.4)

	Three Months Ended June 30, 2026		
	AMCEH & Restricted Subsidiaries/AMC Group (1)	Muvico Group Unrestricted Subsidiaries	Consolidated
(In millions)	(unaudited)	(unaudited)	(unaudited)
Net earnings (loss)	\$ 54.1	\$ (65.5)	\$ (11.4)
Other comprehensive loss:			
Unrealized foreign currency translation adjustments	(16.2)	—	(16.2)
Net pension gain arising during the period	0.2	—	0.2
Other comprehensive loss	(16.0)	—	(16.0)
Total comprehensive income (loss)	\$ 38.1	\$ (65.5)	\$ (27.4)

- (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. Transactions between Holdings and its restricted subsidiaries have been eliminated.
- (2) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the AMC Group level.
- (3) Includes intercompany management fee revenues of \$5.3 million recorded by AMCEH & Restricted Subsidiaries/AMC Group and intercompany license fee revenues of \$4.2 million recorded by Muvico Group

[Table of Contents](#)

Unrestricted Subsidiaries. Corresponding amounts of expense are included in general and administrative: other for Muvico Group Unrestricted Subsidiaries and AMCEH & Restricted Subsidiaries/AMC Group.

	Three Months Ended June 30, 2026		
	AMCEH & Restricted Subsidiaries/AMC Group (3) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Consolidated (unaudited)
Key operating metrics:			
Average ticket price	\$ 11.69	\$ 13.19	\$ 12.11
Attendance (in thousands) (1)	51,385	19,905	71,290
Number of screens operated (2)	7,315	2,215	9,530
Number of theatres operated (2)	673	172	845
Adjusted EBITDA (4)	\$ 219.6	\$ 101.8	\$ 321.4

- (1) Includes consolidated theatres only and excludes screens offline due to construction.
- (2) The screens and theatres of the Muvico Group are operated by Multi-Cinema pursuant to the management agreement.
- (3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement.
- (4) Below is a reconciliation of net loss to Adjusted EBITDA for AMCEH & Restricted Subsidiaries/AMC Group and Muvico Group. The reconciling items below have the same definitions and are of the same nature as the reconciling items presented previously in Management's Discussion and Analysis section of this Form 10-Q.

	Three Months Ended June 30, 2026			
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Eliminations (unaudited)	Consolidated (unaudited)
(In millions)				
Net earnings (loss)	\$ 54.1	\$ (65.5)	\$ —	\$ (11.4)
Plus:				
Income tax provision	3.4	—	—	3.4
Interest expense	71.2	65.3	(0.5)	136.0
Depreciation and amortization	58.0	18.1	—	76.1
Certain operating expense	2.3	—	—	2.3
Equity in earnings of non-consolidated entities	(4.0)	—	—	(4.0)
Attributable EBITDA	0.6	—	—	0.6
Investment expense (income)	0.3	(0.3)	0.5	0.5
Other expense	30.1	84.2	—	114.3
Merger, acquisition and other costs	0.3	—	—	0.3
Stock-based compensation expense	3.3	—	—	3.3
Adjusted EBITDA	\$ 219.6	\$ 101.8	\$ —	\$ 321.4

- (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement.

[Table of Contents](#)

	Six Months Ended June 30, 2026			
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Eliminations (unaudited)	Consolidated (unaudited)
(In millions)				
Revenues				
Admissions	\$ 1,023.9	\$ 417.6	\$ —	\$ 1,441.5
Food and beverage	700.0	223.4	—	923.4
Other theatre (3)	238.3	53.1	(14.2)	277.2
Total revenues	1,962.2	694.1	(14.2)	2,642.1
Operating costs and expenses				
Film exhibition costs	482.3	213.6	—	695.9
Food and beverage costs	137.5	36.6	—	174.1
Operating expense, excluding depreciation and amortization below	658.5	207.2	—	865.7
Rent	336.7	111.2	—	447.9
General and administrative:				
Merger, acquisition and other costs	1.4	—	—	1.4
Other, excluding depreciation and amortization below (3)	119.5	7.6	(14.2)	112.9
Depreciation and amortization	115.6	36.2	—	151.8
Operating costs and expenses	1,851.5	612.4	(14.2)	2,449.7
Operating income	110.7	81.7	—	192.4
Other expense, net:				
Other expense	32.2	25.0	—	57.2
Interest expense:				
Corporate borrowings	104.6	131.2	—	235.8
Finance lease obligations	3.2	—	—	3.2
Non-cash NCM exhibitor services agreement	36.9	—	—	36.9
Intercompany interest expense (income), net	1.2	(1.2)	—	—
Investment income	(17.4)	(0.4)	—	(17.8)
Total other expense, net	160.7	154.6	—	315.3
Loss before income taxes	(50.0)	(72.9)	—	(122.9)
Income tax provision (2)	5.6	—	—	5.6
Net loss	\$ (55.6)	\$ (72.9)	\$ —	\$ (128.5)

	Six Months Ended June 30, 2026		
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Consolidated (unaudited)
(In millions)			
Net loss	\$ (55.6)	\$ (72.9)	\$ (128.5)
Other comprehensive loss:			
Unrealized foreign currency translation adjustments	(31.7)	—	(31.7)
Net pension gain arising during the period	0.2	—	0.2
Other comprehensive loss	(31.5)	—	(31.5)
Total comprehensive loss	\$ (87.1)	\$ (72.9)	\$ (160.0)

- (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement. Transactions between Holdings and its restricted subsidiaries have been eliminated.
- (2) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the AMC Group level.

[Table of Contents](#)

- (3) Includes intercompany management fee revenues of \$7.6 million recorded by AMCEH & Restricted Subsidiaries/AMC Group and intercompany license fee revenues of \$6.6 million recorded by Muvico Group Unrestricted Subsidiaries. Corresponding amounts of expense are included in general and administrative: other for Muvico Group Unrestricted Subsidiaries and AMCEH & Restricted Subsidiaries/AMC Group.

	Six Months Ended June 30, 2026		
	AMCEH & Restricted Subsidiaries/AMC Group (3) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Consolidated (unaudited)
Key operating metrics:			
Average ticket price	\$ 11.70	\$ 13.30	\$ 12.12
Attendance (in thousands) (1)	87,502	31,410	118,912
Number of screens operated (2)	7,315	2,215	9,530
Number of theatres operated (2)	673	172	845
Adjusted EBITDA (4)	\$ 241.7	\$ 118.0	\$ 359.7

- (1) Includes consolidated theatres only and excludes screens offline due to construction.
- (2) The screens and theatres of the Muvico Group are operated by Multi-Cinema pursuant to the management agreement.
- (3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement.
- (4) Below is a reconciliation of net loss to Adjusted EBITDA for AMCEH & Restricted Subsidiaries/AMC Group and Muvico Group. The reconciling items below have the same definitions and are of the same nature as the reconciling items presented previously in Management's Discussion and Analysis section of this Form 10-Q.

	Six Months Ended June 30, 2026			
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Eliminations (unaudited)	Consolidated (unaudited)
(In millions)				
Net loss	\$ (55.6)	\$ (72.9)	\$ —	\$ (128.5)
Plus:				
Income tax provision	5.6	—	—	5.6
Interest expense	145.9	131.2	(1.2)	275.9
Depreciation and amortization	115.6	36.2	—	151.8
Certain operating expense	1.9	0.1	—	2.0
Equity in earnings of non-consolidated entities	(6.7)	—	—	(6.7)
Attributable EBITDA	0.8	—	—	0.8
Investment income	(17.4)	(1.6)	1.2	(17.8)
Other expense, net	39.6	25.0	—	64.6
Merger, acquisition and other costs	1.4	—	—	1.4
Stock-based compensation expense	10.6	—	—	10.6
Adjusted EBITDA	\$ 241.7	\$ 118.0	\$ —	\$ 359.7

- (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement.

	As of June 30, 2026			
	AMCEH & Restricted Subsidiaries/AMC Group (3) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Eliminations (unaudited)	Consolidated (unaudited)
(In millions, except share data)				
ASSETS				
Current assets:				
Cash and cash equivalents (1)	\$ 352.9	\$ 425.5	\$ —	\$ 778.4
Restricted cash	41.1	—	—	41.1
Receivables, net	121.4	4.2	—	125.6
Other current assets	76.9	16.2	—	93.1
Total current assets	592.3	445.9	—	1,038.2
Property, net	990.7	324.6	—	1,315.3
Operating lease right-of-use assets, net	2,260.2	704.0	—	2,964.2
Intangible assets, net	41.6	104.4	—	146.0
Goodwill	2,377.6	—	—	2,377.6
Other long-term assets	201.7	0.6	—	202.3
Intercompany receivables (2)	—	1,943.2	(1,943.2)	—
Investment in subsidiary	607.1	—	(607.1)	—
Total assets	\$ 7,071.2	\$ 3,522.7	\$ (2,550.3)	\$ 8,043.6
LIABILITIES AND STOCKHOLDERS' DEFICIT				
Current liabilities:				
Accounts payable	\$ 327.9	\$ 68.8	\$ —	\$ 396.7
Accrued expenses and other liabilities	295.1	37.0	—	332.1
Deferred revenues and income	440.2	12.4	—	452.6
Current maturities of corporate borrowings	139.0	9.9	—	148.9
Current maturities of finance lease liabilities	7.4	—	—	7.4
Current maturities of operating lease liabilities	413.6	146.8	—	560.4
Total current liabilities	1,623.2	274.9	—	1,898.1
Corporate borrowings	1,708.5	1,994.2	—	3,702.7
Finance lease liabilities	45.2	—	—	45.2
Operating lease liabilities	2,605.8	644.8	—	3,250.6
Exhibitor services agreement	455.9	—	—	455.9
Deferred tax liability, net (4)	36.1	—	—	36.1
Intercompany payables (2)	1,943.2	—	(1,943.2)	—
Other long-term liabilities	106.0	1.7	—	107.7
Total liabilities	8,523.9	2,915.6	(1,943.2)	9,496.3
Commitments and contingencies				
Stockholders' or member's equity (deficit):				
Preferred stock	—	—	—	—
Class A common stock	8.9	—	—	8.9
Additional paid-in capital	7,719.8	819.6	(819.6)	7,719.8
Accumulated other comprehensive loss	(73.7)	—	—	(73.7)
Accumulated deficit	(9,107.7)	(212.5)	212.5	(9,107.7)
Total stockholders' or member's equity (deficit)	(1,452.7)	607.1	(607.1)	(1,452.7)
Total liabilities and stockholders' or member's equity (deficit)	\$ 7,071.2	\$ 3,522.7	\$ (2,550.3)	\$ 8,043.6

- (1) The cash held in bank accounts differs from the book balance due to deposits in transit, payments in transit, and certain cash equivalents.
- (2) Intercompany receivables (payables) includes intercompany loans, fees receivable/payable pursuant to the management agreement and intellectual property license agreement, the intercompany receivable/payable created by allocating the Muvico Term Loans borrowings between Holdings and Muvico, and other intercompany balances created as a result of the 2025 Refinancing Transactions and 2024 Refinancing Transactions.
- (3) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement.

- (4) Muvico is a disregarded entity for federal and state income tax purposes with all tax expense and deferred taxes recorded at the AMC Group level.

(In millions)	Six Months Ended June 30, 2026		
	AMCEH & Restricted Subsidiaries/AMC Group (1) (unaudited)	Muvico Group Unrestricted Subsidiaries (unaudited)	Consolidated (unaudited)
Net loss	\$ (55.6)	\$ (72.9)	\$ (128.5)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:			
Depreciation and amortization	115.6	36.2	151.8
Loss on extinguishment of debt	30.1	33.0	63.1
Gain on derivatives	—	(8.4)	(8.4)
Deferred income taxes	0.4	—	0.4
Gain on investments in Hycroft	(16.5)	—	(16.5)
Amortization of net discount on corporate borrowings to interest expense	4.9	0.6	5.5
Amortization of deferred financing costs to interest expense	4.0	6.1	10.1
PIK interest expense	—	30.9	30.9
Non-cash portion of stock-based compensation	10.6	—	10.6
Equity in earnings from non-consolidated entities, net of distributions	(4.0)	—	(4.0)
Lease incentives	24.6	—	24.6
Non-cash rent benefit	(50.6)	(7.9)	(58.5)
Net periodic pension cost	1.0	—	1.0
Change in assets and liabilities:			
Receivables	24.0	1.6	25.6
Other assets	(21.0)	20.1	(0.9)
Accounts payable	(8.6)	26.8	18.2
Accrued expenses and other liabilities	(34.9)	8.7	(26.2)
Intercompany receivables and payables	(254.3)	254.3	—
Other, net	7.2	0.9	8.1
Net cash provided by (used in) operating activities	(223.1)	330.0	106.9
Cash flows from investing activities:			
Capital expenditures	(71.1)	(20.4)	(91.5)
Proceeds from disposition of long-term assets	2.2	—	2.2
Proceeds from sale of Hycroft	29.7	—	29.7
Net cash used in investing activities	(39.2)	(20.4)	(59.6)
Cash flows from financing activities:			
Net proceeds from equity issuances	334.6	—	334.6
Proceeds from issuance of Odeon Term Loans due 2031	416.5	—	416.5
Principal payments under Odeon Senior Secured Notes due 2027	(400.0)	—	(400.0)
Premium paid to extinguish Odeon Senior Secured Notes due 2027	(12.8)	—	(12.8)
Principal payments under finance lease obligations	(3.0)	—	(3.0)
Scheduled principal payments under term loan borrowings	(5.0)	(5.0)	(10.0)
Cash used to pay deferred financing costs	(19.8)	(4.2)	(24.0)
Taxes paid for restricted unit withholdings	(3.7)	—	(3.7)
Proceeds (payments) of intercompany loans	53.6	(53.6)	—
Net cash provided by (used in) financing activities	360.4	(62.8)	297.6
Effect of exchange rate changes on cash and cash equivalents and restricted cash	(2.7)	—	(2.7)
Net increase in cash and cash equivalents and restricted cash	95.4	246.8	342.2
Cash and cash equivalents and restricted cash at beginning of period	298.6	178.7	477.3
Cash and cash equivalents and restricted cash at end of period	\$ 394.0	\$ 425.5	\$ 819.5

- (1) This column provides the information required to be presented for (i) Holdings and its Restricted Subsidiaries under the indenture governing the Existing 7.5% Notes and (ii) AMC Group under the Muvico Credit Agreement.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

In the ordinary course of business, our financial results are exposed to fluctuations in interest rates and foreign currency exchange rates. We manage the risk of fluctuations in interest rates by maintaining an appropriate balance between our fixed and floating-rate debt. In accordance with applicable guidance, we presented a sensitivity analysis showing the potential impact to net earnings (loss) of changes in interest rates and foreign currency exchange rates. For the six months ended June 30, 2026 and June 30, 2025, our analysis utilized a hypothetical 100 basis-point increase or decrease to the average interest rate on our variable rate debt instruments to illustrate the potential impact to interest expense of changes in interest rates. Our analysis also utilized a hypothetical 100 basis-point increase or decrease to market interest rates on our performance-based variable-rate financial instruments and fixed rate financial instruments to illustrate the potential impact to fair value of changes in interest rates.

Similarly, for the same period, our analysis used a uniform and hypothetical 10% increase in foreign currency translation rates to depict the potential impact on net earnings (loss) due to changes in foreign exchange rates. These market risk instruments and the potential impacts to the condensed consolidated statements of operations are presented below.

Market risk on performance-based & market-based variable-rate hybrid financial instruments. As of June 30, 2026, we had an aggregate of \$1,984.2 million outstanding principal amount of our Muvico Term Loans which bear interest, at our option, at rates equal to either (i) a base rate plus a margin of between 500 and 600 basis points depending on the total leverage ratio of the Company and its subsidiaries on a consolidated basis (the “Total Leverage Ratio”) or (ii) Term SOFR plus a margin of between 600 and 700 basis points depending on the Total Leverage Ratio.

The rate in effect for the outstanding Muvico Term Loans was 10.639% per annum as of June 30, 2026, and 11.318% per annum for the Muvico Term Loans as of June 30, 2025.

Increases in market interest rates would cause interest expense to increase and earnings before income taxes to decrease. The change in interest expense and earnings before income taxes would be dependent upon the weighted average outstanding borrowings during the reporting period following an increase in market interest rates. A 100-basis point change in market interest rates would have increased or decreased interest expense on the Muvico Term Loans by approximately \$10.0 million during the six months ended June 30, 2026.

A 100-basis point change in market interest rates would have increased or decreased interest expense on the Muvico Term Loans by \$10.0 million during the six months ended June 30, 2025.

Market risk on performance-based variable-rate financial instruments. As of June 30, 2026, we had an aggregate of \$903.4 million outstanding principal amount of our New 2029 Notes which bear interest ranging from 11.5% to 15.0% per annum depending on the Total Leverage Ratio. The rate in effect for the outstanding New 2029 Notes was 15.0% per annum at June 30, 2026.

A 100-basis point change in market interest rates would have caused an increase (decrease) in the fair value of our performance-based variable-rate financial instruments of approximately \$21.6 million and \$(21.0) million, respectively, as of June 30, 2026.

Market risk on fixed-rate financial instruments. Included in corporate borrowings as of June 30, 2026, were principal amounts of \$116.1 million of our Existing Exchangeable Notes, \$360.0 million of our Existing 7.5% Notes, \$425.0 million of our Odeon Term Loans due 2031, and \$125.5 million of our Senior Subordinated Notes due 2027. A 100-basis point change in market interest rates would have caused an increase or (decrease) in the fair value of our fixed rate financial instruments of approximately \$28.2 million and \$(27.1) million, respectively, as of June 30, 2026.

Included in corporate borrowings as of June 30, 2025, were principal amounts of \$444.7 million of our Existing Exchangeable Notes, \$950.0 million of our Existing 7.5% Notes, \$131.2 million of our Second Lien Notes, \$400.0 million of our Odeon Notes due 2027, \$41.9 million of our Senior Subordinated Notes due 2026, and \$125.5 million of our Senior Subordinated Notes due 2027. A 100-basis point change in market interest rates would have caused an increase or (decrease) in the fair value of our fixed rate financial instruments of approximately \$51.2 million and \$(49.3) million, respectively, as of June 30, 2025.

Foreign currency exchange rate risk. We are also exposed to market risk arising from changes in foreign currency exchange rates affecting our International markets operations. International markets revenues and operating

expenses are transacted in British Pounds, Euros, Swedish Krona and Norwegian Krone. U.S. GAAP requires that our subsidiaries use the currency of the primary economic environment in which they operate as their functional currency. If any international subsidiary operates in a highly inflationary economy, U.S. GAAP requires that the U.S. dollar be used as the functional currency. Currency fluctuations in the countries in which we operate result in us reporting exchange gains (losses) or foreign currency translation adjustments. Based upon the functional currencies in the International markets as of June 30, 2026, holding everything else constant, a hypothetical 10% increase in foreign currency translation rates to depict the potential impact to net loss of changes in foreign exchange rates would increase the aggregate net loss of our International markets for the six months ended June 30, 2026, by approximately \$6.2 million. Based upon the functional currencies in the International markets as of June 30, 2025, holding everything else constant, a hypothetical 10% increase in foreign currency translation rates to depict the potential impact to net loss of changes in foreign exchange rates would increase the aggregate net loss of our International markets for the six months ended June 30, 2025, by approximately \$3.0 million.

Our foreign currency translation rates increased by approximately 2.0% for the three months ended June 30, 2026 compared to the three months ended June 30, 2025, and increased 6.0% for the six months ended June 30, 2026, compared to the six months ended June 30, 2025.

Item 4. Controls and Procedures.

(a) Evaluation of disclosure controls and procedures.

The Company maintains a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in its filings under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that material information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The Company's Chief Executive Officer and Chief Financial Officer have evaluated these disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q and have determined that such disclosure controls and procedures were effective.

(b) Changes in internal control.

There has been no change in our internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during our most recent calendar quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings

On May 4, 2023, the Company filed a lawsuit in the Superior Court of the State of Delaware against seventeen insurers participating in its directors & officers insurance program, seeking recovery for losses incurred in connection with its defense and settlement of *In re AMC Entertainment Holdings, Inc. Stockholder Litigation*, No. 2023-0215-MTZ (Del. Ch.), including the settlement payment. The insurance recovery action is captioned *AMC Entertainment Holdings, Inc. v. XL Specialty Insurance Co., et al.*, Case No. N23C-05-045 AML CCLD (Del. Super. May 4, 2023) (the "Coverage Action"). In the suit, AMC sought up to \$80 million in coverage under its Executive and Corporate Securities Liability Insurance Policies sold by the defendants, which provide coverage for the policy period of January 1, 2022 through January 1, 2023 (the "Policies") in excess of a \$10 million deductible. The primary insurer in the Coverage Action paid its full \$5.0 million limit and the Company reached confidential settlement agreements with all but one insurer in the Coverage Action.

The remaining insurer contested whether it owed coverage for the settlement payment, claiming it does not constitute a "Loss" under its insurance policy (the "Loss Defense"). On February 28, 2025, the court denied a motion for summary judgment by the remaining insurer in the Coverage Action, and granted the Company's motion for summary judgment on the Loss Defense, ruling that the settlement payment constituted a covered loss. On April 9, 2025, the court entered a final judgment in favor of the Company in the amount of \$5.0 million plus pre-judgment interest of \$0.7 million. On December 9, 2025, the Supreme Court of the State of Delaware affirmed the Superior

Court's decision in favor of the Company. Shortly thereafter, the remaining insurer paid the Company its full limits, plus pre- and post-judgment interest and the case was closed.

AMC also had claims for coverage from additional insurers, however, those insurers' policies contain mandatory arbitration provisions, so they were not included in the Coverage Action. On January 24, 2025, the Company sent a notice of arbitration to the four remaining insurers with mandatory arbitration provisions on the same grounds as the Coverage Action. In April 2026, the Company entered into confidential settlement agreements with each of the additional insurers, and this matter is fully resolved.

On October 31, 2025, a purported securities class action captioned *Simons v. AMC Entertainment Holdings, Inc.*, No. 1:25-cv-09042-JLR, was filed by a purported former holder of AMC Preferred Equity Units against the Company in the United States District Court for the Southern District of New York. The complaint asserts a claim under Section 10(b) of the Securities Exchange Act of 1934 based on allegedly false and misleading public statements and omissions by the Company during the period from August 18, 2022 to November 1, 2023 concerning the conversion of the AMC Preferred Equity Units. The complaint alleges damages of at least \$178 million, plus pre-judgment interest. On June 8, 2026, Plaintiff informed the court that he no longer intends to pursue claims on a class-wide basis and sought leave to file an amended complaint to assert individual claims. On June 9, 2026, the court granted Plaintiff's request for leave to file an amended complaint. The Company intends to defend the action vigorously.

On December 5, 2025, an action captioned *Masoner v. AMC Entertainment Holdings, Inc. et al.*, No. N25C-12-022 was filed by two purported AMC stockholders against the Company, Adam Aron, and unspecified members of the Company's board of directors in the Superior Court of the State of Delaware. The complaint asserted claims for, among other things, fraud, fraud on the court, breach of fiduciary duty, unjust enrichment, and conspiracy based on the 2023 settlement of the action captioned *In re AMC Entertainment Holdings, Inc. Stockholder Litigation* No. 2023-0215-MTZ (Del. Ch.). Plaintiffs seek, among other things, monetary damages of approximately \$4.2 million, disgorgement of approximately \$18 million, and declaratory, equitable, and injunctive relief. On March 18, 2026, defendants filed a motion to dismiss the complaint. On March 24, 2026, plaintiffs filed an amended complaint, which added certain current and former directors of the Company's board of directors as defendants. On April 8, 2026, defendants filed a motion to dismiss the amended complaint, which is fully briefed and remains pending.

Item 1A. Risk Factors

Reference is made to Part I Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2025, which sets forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. Except as set forth below, there have been no material changes to the risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2025.

There has been significant recent dilution and there may continue to be additional future dilution of our Common Stock, which could adversely affect the market price of shares of our Common Stock.

From January 1, 2020 through July 22, 2026, the outstanding shares of our Common Stock have increased by 887,396,630 shares (on a Reverse Stock Split adjusted basis) in a combination of at-the-market sales, forward sales, conversion of Series A Convertible Participating Preferred Stock, shareholder litigation settlement, conversion of Class B common stock, conversion of notes, exchanges of notes, consent fee payments, transaction fee payments, and equity grant vesting. On March 14, 2023, we held a special meeting of our stockholders and obtained the requisite stockholder approval for the certain amendments to the Company's Third Amended and Restated Certificate of Incorporation to increase the Company's total number of authorized shares of Common Stock and to effectuate a reverse split at a ratio of one share of Common Stock for every ten shares of Common Stock (the "Charter Amendments") and on August 14, 2023, we filed the amendment to our certificate of incorporation implementing the Charter Amendments, effective as of August 24, 2023. In accordance with the Charter Amendments, we increased the total number of authorized shares of Common Stock from 524,173,073 to 550,000,000 shares of Common Stock and effectuated a reverse stock split at a ratio of one share of Common Stock for every ten shares of Common Stock outstanding (the "Reverse Stock Split"). In accordance with the terms of the Certificate of Designations governing the Series A Convertible Participating Preferred Stock, following the effectiveness of the Charter Amendments all outstanding shares of our Series A Convertible Participating Preferred Stock converted into 99,540,642 shares of Common Stock. In addition, as described below, on December 10, 2025, following approval by our stockholders at the Annual Meeting (as defined herein), we increased the total number of authorized shares of Common Stock from 550,000,000 to 1,100,000,000.

[Table of Contents](#)

On July 22, 2024, the Company and certain of its subsidiaries consummated a series of refinancing transactions (the “2024 Refinancing Transactions”) pursuant to which Muvico issued \$414.4 million aggregate principal amount of Existing Exchangeable Notes that are exchangeable into shares of Common Stock. On July 1, 2025, the Company and Muvico commenced a series of further refinancing transactions with certain of its debt holders (the “2025 Refinancing Transactions”) pursuant to which the Company issued 79,800,000 shares of Common Stock in exchange for \$143.0 million aggregate principal amount of Existing Exchangeable Notes. Subsequently, on July 24, 2025, the Company exchanged approximately \$194.4 million aggregate principal amount of Existing Exchangeable Notes for Muvico’s New Exchangeable Notes on a dollar-for-dollar basis. On September 30, 2025, \$39.9 million aggregate principal of New Exchangeable Notes were cancelled pursuant to a downward adjustment feature in the New Exchangeable Notes, which represented the maximum possible downward adjustment under the New Exchangeable Notes.

As of June 30, 2026, approximately \$116.1 million aggregate principal amount of Existing Exchangeable Notes were outstanding, including interest paid-in-kind in the form of additional Existing Exchangeable Notes (“PIK Notes”) to the holders thereof. If the outstanding Existing Exchangeable Notes were exchanged fully into shares of Common Stock as of June 30, 2026, they would be converted into an aggregate of approximately 23.1 million shares of Common Stock. If the outstanding Existing Exchangeable Notes were converted fully into shares of our Common Stock at maturity, and we were to elect to issue additional Existing Exchangeable Notes as PIK Notes on such outstanding Existing Exchangeable Notes and PIK Notes to the full extent permitted during the life of the Existing Exchangeable Notes (without regard to any limitations on our authorized share capital or on the exchange therein and giving effect to the changes in the applicable make-whole fee over the period), such Existing Exchangeable Notes (including PIK Notes) would be convertible at maturity into an aggregate of approximately 27.8 million shares of Common Stock.

At the Company’s 2025 Annual Meeting of Stockholders held on December 10, 2025 (the “Annual Meeting”), the Company’s stockholders approved an amendment to the Company’s certificate of incorporation to increase the total number of authorized shares of Common Stock from 550,000,000 shares to 1,100,000,000 shares (the “Authorized Share Increase”), which additional shares may be used for at-the-market sales, exchanges of notes, private placement transactions, equity grant vesting and other dilutive issuances. Accordingly, we may issue additional shares of Common Stock to raise cash to bolster our liquidity, to repay, refinance, redeem or exchange indebtedness (including expenses, accrued interest and premium, if any), for working capital, to finance strategic initiatives and future acquisitions, and to settle exchanges of the Existing Exchangeable Notes, including any PIK Notes, or for other purposes. Furthermore, in connection with the 2025 Refinancing Transactions and the issuance of the New Exchangeable Notes, we paid a consent fee to certain consenting holders of our Existing Exchangeable Notes of 10.9 million shares of Common Stock. Additionally, as consent fees for amending their respective indentures to provide us with greater flexibility to refinance our capital structure, we paid a consent fee of 4.5 million shares of Common Stock to consenting holders of the New Exchangeable Notes and 17.7 million shares of Common Stock to consenting holders of the New 2029 Notes. In addition, in connection with the Authorized Share Increase, the New Exchangeable Notes became exchangeable for shares of our Common Stock. In May 2026, we exchanged 142.1 million shares of Common Stock for the New Exchangeable Notes, including accrued and unpaid interest, representing the exchange in full of the New Exchangeable Notes for shares of Common Stock.

As of July 22, 2026, there were 892,604,638 shares of Common Stock issued and outstanding. In addition, as described above, shares of Common Stock may be used to settle exchanges of the Existing Exchangeable Notes, including any additional Existing Exchangeable Notes or interest paid in-kind by issuing Existing Exchangeable Notes, or for other purposes. We may also issue preferred equity securities or securities convertible into, or exchangeable for, or that represent the right to receive, shares of Common Stock or acquire interests in other companies, or other assets by using a combination of cash and shares of Common Stock, or just shares of Common Stock. Additionally, vesting of outstanding awards pursuant to our equity compensation program results in the issuance of new shares of Common Stock, net of any shares withheld to cover tax withholding obligations upon vesting. Any of these events may significantly dilute the ownership interests of current stockholders, reduce our earnings per share or have an adverse effect on the price of our shares of Common Stock.

As of July 22, 2026, we had approximately 168,258,701 authorized shares of Common Stock that have not been issued or reserved for issuance in connection with our employee plans or exchanges under the Existing Exchangeable Notes. As a result, we may in the future seek to obtain the requisite stockholder approval for the authorization of an additional number of authorized and unissued and unreserved shares of Common Stock, which may be used for at-the-market sales, exchanges of notes, private placement transactions, equity grant vesting and other dilutive issuances. These future issuances may be dilutive and may result in a decline in the market price of our Common Stock. The remaining authorized shares assume that no additional PIK interest is paid on the Existing Exchangeable Notes.

The market price and trading volume of our shares of Common Stock have experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Common Stock to incur substantial losses.

The market prices and trading volume of our shares of Common Stock have experienced, and may continue to experience, extreme volatility, which could cause purchasers of our Common Stock to incur substantial losses. For example, during 2026 to date, the market price of our Common Stock has fluctuated from an intra-day low on the New York Stock Exchange (“NYSE”) of \$0.93 per share on March 27, 2026 to an intra-day high on the NYSE of \$2.96 on June 22, 2026. The last reported sale price of our Common Stock on the NYSE on July 22, 2026, was \$2.25 per share. During 2026 to date, daily trading volume ranged from approximately 14,347,700 to 186,756,900 shares.

We believe that the volatility and our market prices have reflected and may continue to reflect market and trading dynamics unrelated to our underlying business, or macro or industry fundamentals, and we do not know how long these dynamics will last.

Extreme fluctuations in the market price of our Common Stock have been accompanied by reports of strong and atypical retail investor interest, including on social media and online forums. The market volatility and trading patterns we have experienced create several risks for investors, including the following:

- the market price of our Common Stock has experienced and may continue to experience rapid and substantial increases or decreases unrelated to our operating performance or prospects, or macro or industry fundamentals, and substantial increases may be significantly inconsistent with the risks and uncertainties that we continue to face;
- factors in the public trading market for our Common Stock may include the sentiment of retail investors (including as may be expressed on financial trading and other social media sites and online forums), the direct access by retail investors to broadly available trading platforms, the amount and status of short interest in our securities, access to margin debt, trading in options and other derivatives on our Common Stock and any related hedging and other trading factors;
- our market capitalization, as implied by various trading prices, currently reflects valuations that diverge significantly from historical valuations, and to the extent these valuations reflect trading dynamics unrelated to our financial performance or prospects, purchasers of our Common Stock could incur substantial losses if there are declines in market prices;
- to the extent volatility in our Common Stock is caused, or may from time to time be caused, as has widely been reported, by a “short squeeze” in which coordinated trading activity causes a spike in the market price of our Common Stock as traders with a short position make market purchases to avoid or to mitigate potential losses, investors purchase at inflated prices unrelated to our financial performance or prospects, and may thereafter suffer substantial losses as prices decline once the level of short-covering purchases has abated; and
- if the market price of our Common Stock declines, investors may be unable to resell shares of our Common Stock at or above the price at which their investment was made. Our Common Stock may continue to fluctuate or decline significantly in the future, which may result in substantial losses.

Future increases or decreases in the market price of our Common Stock may not coincide in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our shares of Common Stock may fluctuate dramatically, and may decline rapidly, regardless of any developments in our business. Overall, there are various factors, many of which are beyond our control, that could negatively affect the market price of our Common Stock or result in fluctuations in the price or trading volume of our Common Stock, including:

- actual or anticipated variations in our annual or quarterly results of operations, including our earnings estimates and whether we meet market expectations with regard to our earnings;
- restrictions on our ability to pay dividends or other distributions;
- publication of research reports by analysts or others about us or the motion picture exhibition industry, which may be unfavorable, inaccurate, inconsistent or not disseminated on a regular basis;
- changes in market interest rates that may cause purchasers of our shares to demand a different yield;
- changes in market valuations of similar companies;
- market reaction to any additional equity, debt or other securities that we may issue in the future, and which may or may not dilute the holdings of our existing stockholders;

- additions or departures of key personnel;
- actions by institutional or significant stockholders;
- short interest in our securities and the market response to such short interest;
- the dramatic increase or decrease in the number of individual holders of our Common Stock and their participation in social media platforms targeted at speculative investing;
- speculation in the press or investment community about our company or industry;
- strategic actions by us or our competitors, such as acquisitions or other investments;
- legislative, administrative, regulatory or other actions affecting our business or our industry, including positions taken by the Internal Revenue Service;
- strategic actions taken by motion picture studios such as the shuffling of film release dates;
- investigations, proceedings, or litigation that involve or affect us;
- ongoing impacts upon the industry resulting from the COVID-19 pandemic;
- the occurrence of any of the other risk factors included or incorporated by reference in our Annual Report on Form 10-K; and
- general market and economic conditions.

The Company's current equity incentive plan has insufficient shares to make grants at historic levels. Without additional shares authorized for the plan, the Company could experience difficulties retaining and hiring executives due to its inability to issue compensatory equity awards and could experience an adverse impact on its cash flow or adverse accounting consequences from alternative forms of compensation.

The current equity incentive plan of the Company has insufficient available shares to make additional grants at historic levels. As required by NYSE rules, the Company intends to ask its stockholders for approval to allocate additional shares to the plan at its 2026 annual meeting. There can be no guarantee that the stockholders will approve additional shares. The absence of shares available under the equity incentive plan may create challenges for executive recruitment and retention. Absent additional shares, the Company could issue equity-related awards to be settled in cash. The issuance of such awards may mitigate short-term risks related to executive recruitment and retention, but cash settlements of these awards would negatively impact cash flow and would require the Company to account for these awards based on the fair value of the related equity at the end of each reporting period, giving effect to the portion of services rendered during the requisite service periods. Until such time as the stockholders approve additional shares for the equity incentive plan, equity-related awards made to executives would need to be settled in cash. Continued issuance of cash-settled awards may not be sustainable given the Company's recent cash flow challenges.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Except as reported in Item 3.02 of our Current Reports on Form 8-K filed with the SEC on May 5, 2026 and May 13, 2026 which are incorporated by reference into this Quarterly Report on Form 10-Q, there were no sales of unregistered securities during the quarter ended June 30, 2026.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

Rule 10b5-1 Trading Arrangements

In the second quarter of 2026, no director or officer (as defined in Exchange Act Rule 16a-1(f)) of AMC adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement for the purchase or sale of securities of the Company, within the meaning of Item 408 of Regulation S-K. Additionally, Holdings did not adopt or terminate any Rule 10b5-1 trading arrangement during the second quarter of 2026.

Item 6. Exhibits.

EXHIBIT INDEX

EXHIBIT NUMBER	DESCRIPTION
<u>*3.1</u>	<u>Fourth Amended and Restated Certificate of Incorporation of AMC Entertainment Holdings, Inc., dated as of December 10, 2025.</u>
<u>10.1</u>	<u>Odeon Credit Agreement, by and among Odeon Finco PLC, as borrower, Odeon Cinemas Group Limited, as the company, the lenders party thereto and U.S. Bank Trust Company, National Association, as administrative agent and security agent, dated as of April 17, 2026 (incorporated by reference from Exhibit 10.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on April 17, 2026).</u>
<u>10.2</u>	<u>Guarantee Agreement, by and between AMC Entertainment Holdings, Inc. and U.S. Bank Trust Company, National Association, dated as of April 17, 2026 (incorporated by reference from Exhibit 10.2 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on April 17, 2026).</u>
<u>10.3</u>	<u>Second Amendment to Muvico Credit Agreement, by and among AMC Entertainment Holdings, Inc. and Muvico, LLC, as borrowers, and Wilmington Savings Fund Society, FSB, as administrative agent and as collateral agent, dated as of April 17, 2026 (incorporated by reference from Exhibit 10.3 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on April 17, 2026).</u>
<u>10.4</u>	<u>Placement Agency Agreement, dated June 23, 2026, between the Company and Roth Capital Partners, LLC (incorporated by reference from Exhibit 10.1 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on June 23, 2026).</u>
<u>10.5</u>	<u>Securities Purchase Agreement, dated June 23, 2026, between the Company and the purchasers party thereto (incorporated by reference from Exhibit 10.2 to AMC's Current Report on Form 8-K (File No. 1-33892) filed on June 23, 2026).</u>
<u>*31.1</u>	<u>Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
<u>*31.2</u>	<u>Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
<u>*32.1</u>	<u>Section 906 Certifications of Adam M. Aron (Chief Executive Officer) and Sean D. Goodman (Chief Financial Officer) furnished in accordance with Securities Act Release 33-8212.</u>
**101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
**101.SCH	Inline XBRL Taxonomy Extension Schema Document
**101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
**101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
**101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
**101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
**104	Cover Page Interactive Data File (formatted as inline XBRL and contained as Exhibit 101)

* Filed or furnished herewith, as applicable.

** Submitted electronically with this Report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMC ENTERTAINMENT HOLDINGS, INC.

Date: July 23, 2026

/s/ ADAM M. ARON

Adam M. Aron

Chairman of the Board, Chief Executive Officer and President

Date: July 23, 2026

/s/ SEAN D. GOODMAN

Sean D. Goodman

Executive Vice President, International Operations, Chief Financial Officer and Treasurer

**FOURTH AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
OF
AMC ENTERTAINMENT HOLDINGS, INC.**

AMC Entertainment Holdings, Inc., a corporation organized and existing under the laws of the State of Delaware (hereinafter, the "Corporation"), hereby certifies as follows

FIRST: The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on June 6, 2007.

SECOND: This Fourth Amended and Restated Certificate of Incorporation has been duly adopted by the board of directors of the Corporation (the "Board of Directors") and by the stockholders in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware and amends and restates the provisions of the Third Amended and Restated Certificate of Incorporation of the Corporation.

THIRD: The text of the Third Amended and Restated Certificate of Incorporation of the Corporation is hereby amended and restated in its entirety to read as follows:

**ARTICLE I
NAME**

The name of the Corporation is AMC Entertainment Holdings, Inc. (the "Corporation").

**ARTICLE II
REGISTERED OFFICE**

The address of the Corporation's registered office in the State of Delaware is to be located at 1521 Concord Pike, Suite 201, Wilmington, New Castle County, Delaware 19803 and the name of its registered agent at such address is Corporate Creations Network Inc.

**ARTICLE III
PURPOSE**

The purpose or purposes of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware as the same exists or may hereafter be amended (the "DGCL").

**ARTICLE IV
CAPITAL STOCK**

A. The total number of shares of capital stock that the Corporation has authority to issue is 1,150,000,000 shares, consisting of (i) 1,100,000,000 shares of Class A Common Stock, par value \$0.01 per share (the "Common Stock") and (ii) 50,000,000 shares of Preferred Stock, par value

\$0.01 per share (the “Preferred Stock”).

B. Except as otherwise provided by law or as set forth herein, the shares of stock of the Corporation, regardless of class, may be issued by the Corporation from time to time in such amounts, for such consideration and for such corporate purposes as the Board of Directors may from time to time determine.

C. The Board of Directors is hereby expressly authorized, by resolution or resolutions, to establish, out of the unissued shares of Preferred Stock, one or more series of Preferred Stock and to determine, with respect to each such series, the number of shares constituting such series and the designation of such series, the voting powers (if any) of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional and other special rights of each series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

D. The number of authorized shares of any of the Common Stock or the Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the stock of the Corporation entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the DGCL (or any successor provision thereto), and no vote of the holders of any of the Common Stock or the Preferred Stock voting separately as a class shall be required therefor.

E. Each holder of record of Class A Common Stock shall have one vote for each share of Class A Common Stock that is outstanding in his, her or its name on the books of the Corporation and which is entitled to vote.

F. In the election of directors, stockholders shall be entitled to cast for any one candidate no greater number of votes than the number of shares held by such stockholder; no stockholder shall be entitled to cumulate votes on behalf of any candidate. Except as otherwise required by law, holders of record of Common Stock shall not be entitled to vote on any amendment to this Fourth Amended and Restated Certificate of Incorporation (including any certificate of designations relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Fourth Amended and Restated Certificate of Incorporation (including any certificate of designations relating to any series of Preferred Stock) or pursuant to the DGCL.

G. Subject to applicable law and rights, if any, of the holders of any outstanding shares of Preferred Stock or any class or series of stock having a preference over or the right to participate with the Common Stock with respect to the payment of dividends, dividends may be declared and paid on the Common Stock at such times and in such amounts as the Board of Directors in its discretion shall determine.

H. Upon the liquidation, dissolution, distribution of assets or winding up of the Corporation, subject to the rights, if any, of the holders of any outstanding series of Preferred Stock or any class or series of stock having a preference over or the right to participate with the Common Stock with respect to the distribution of assets of the Corporation upon such dissolution, liquidation or winding up of the Corporation, the holders of Common Stock shall be entitled to receive the

assets of the Corporation available for distribution to its stockholders in proportion to the number of shares held by them.

ARTICLE V BOARD OF DIRECTORS

The following provisions are inserted for the management of the business and for the conduct of the affairs of the Corporation and for the purpose of creating, defining, limiting and regulating the powers of the Corporation and its directors and stockholders:

A. The directors of the Corporation, subject to any rights of the holders of shares of any class or series of Preferred Stock to elect directors, shall be classified with respect to the time for which they severally hold office into three classes, as nearly equal in number as possible. One class's initial term will expire at the first annual meeting of the stockholders following the effectiveness of this Certificate of Amendment, another class's initial term will expire at the second annual meeting of the stockholders following the effectiveness of this Certificate of Amendment and another class's initial term will expire at the third annual meeting of stockholders following the effectiveness of this Certificate of Amendment, with directors of each class to hold office until their successors are duly elected and qualified; provided that the term of each director shall continue until the election and qualification of a successor and be subject to such director's earlier death, resignation or removal. At each annual meeting of stockholders of the Corporation beginning with the first annual meeting of stockholders following the filing of this Certificate of Amendment, subject to any rights of the holders of shares of any class or series of Preferred Stock, the successors of the directors whose term expires at that meeting shall be elected to hold office for a term expiring at the annual meeting of stockholders held in the third year following the year of their election. In the case of any increase or decrease, from time to time, in the number of directors of the Corporation, the number of directors in each class shall be apportioned as nearly equal as possible. No decrease in the number of directors shall shorten the term of any incumbent director.

B. The numbers of directors shall be no less than three and no more than 15. Subject to any special rights of any holders of any class or series of Preferred Stock to elect directors, the precise number of directors of the Corporation within the limitations specified in the preceding sentence shall be fixed, and may be altered from time to time, only by resolution of the Board of Directors.

C. Subject to this Article V, the election of directors may be conducted in any manner approved by the officer of the Corporation presiding at a meeting of the stockholders or the directors, as the case may be, at the time when the election is held and need not be by written ballot.

D. Any or all directors of the Corporation (other than the directors, if any, elected by the holders of any series of Preferred Stock, voting separately as one or more series, as the case may be) may be removed at any time either with or without cause by the affirmative vote of holders of at least a majority of the voting power of all the then outstanding shares of stock of the Corporation entitled to vote generally in the election of directors, voting as a single class.

E. Subject to any rights of the holders of shares of any class or series of Preferred Stock, if any, to elect additional directors under specified circumstances, any vacancy in the Board of Directors that results from an increase in the number of directors, from the death, disability, resignation, disqualification, removal of any director or from any other cause shall be filled solely by

a majority of the total number of directors then in office, even if less than a quorum, or by a sole remaining director.

F. All corporate powers and authority of the Corporation (except as at the time otherwise provided by law, by this Fourth Amended and Restated Certificate of Incorporation or by the bylaws of the Corporation) shall be vested in and exercised by the Board of Directors.

ARTICLE VI ACTION BY SHAREHOLDERS

A. Any action required or permitted to be taken at any annual or special meeting of stockholders of the Corporation may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock of the Corporation having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation by delivery to its registered office in Delaware, its principal place of business, or to an officer or agent of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded; provided, however, that if at any time Wanda or its affiliates no longer beneficial owns, in the aggregate, more than 50.0% of the voting power of all the then outstanding shares of stock of the Corporation entitled to vote generally in the election of directors, then any action required or permitted to be taken at any annual or special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of such stockholders and may no longer be effected by any consent in writing.

B. Except as otherwise required by law and subject to the rights, if any, of the holders of any series of Preferred Stock, special meetings of the stockholders of the Corporation for any purpose or purposes may be called at any time pursuant to a resolution of the Board of Directors (and the Chairman of the Board of Directors, the Chief Executive Officer or Secretary of the Corporation shall call the meeting pursuant to such resolution), and special meetings of stockholders of the Corporation may not be called by any other person or persons.

C. The books of the Corporation may (subject to any statutory requirements) be kept outside the State of Delaware as may be designated by the Board of Directors or in the bylaws of the Corporation. Meetings of stockholders may be held within or outside the state of Delaware, as the bylaws of the Corporation may provide.

ARTICLE VII DGCL SECTION 203

The Corporation shall not be governed by Section 203 of the DGCL ("Section 203"), and the restrictions contained in Section 203 shall not apply to the Corporation.

ARTICLE VIII CORPORATE OPPORTUNITIES

To the fullest extent permitted by Section 122(17) of the DGCL and except as may be otherwise expressly agreed in writing by the Corporation and Wanda, the Corporation, on behalf of itself and its subsidiaries, renounces any interest or expectancy of the Corporation and its

subsidiaries in, or in being offered an opportunity to participate in, business opportunities, that are from time to time presented to Wanda or any of its respective officers, directors, agents, stockholders, members, partners, affiliates and subsidiaries (other than the Corporation and its subsidiaries), even if the opportunity is one that the Corporation or its subsidiaries might reasonably be deemed to have pursued or had the ability or desire to pursue if granted the opportunity to do so and no such person shall be liable to the Corporation or any of its subsidiaries for breach of any fiduciary or other duty, as a director or officer or otherwise, by reason of the fact that such person pursues or acquires such business opportunity, directs such business opportunity to another person or fails to present such business opportunity, or information regarding such business opportunity, to the Corporation or its subsidiaries unless, in the case of any such person who is a director or officer of the Corporation, such business opportunity is expressly offered to such director or officer in writing solely in his or her capacity as a director or officer of the Corporation. Any person purchasing or otherwise acquiring any interest in any shares of stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article VIII. Neither the alteration, amendment or repeal of this Article VIII nor the adoption of any provision of this Fourth Amended and Restated Certificate of Incorporation inconsistent with this Article VIII shall eliminate or reduce the effect of this Article VIII in respect of any business opportunity first identified or any other matter occurring, or any cause of action, suit or claim that, but for this Article VIII, would accrue or arise, prior to such alteration, amendment, repeal or adoption.

ARTICLE IX INDEMNIFICATION; LIMITATION OF LIABILITY

A. The personal liability of the directors for monetary damages for breach of fiduciary duty as a director of the Corporation is hereby eliminated to the fullest extent permitted by the DGCL. Any repeal or modification of this Article IX shall not adversely affect any right or protection of a director of the Corporation existing hereunder with respect to any act or omission occurring prior to such repeal or modification,

B. Each person who was or is a party or is made a party, threatened to be made a party to or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "Proceeding"), by reason of the fact that he or she, or a person of whom he or she is the legal representative, is or was a director or officer of the Corporation or is or was serving at the request of the Corporation as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (any such person, an "Indemnitee"), whether the basis of such Proceeding is alleged action in an official capacity as a director, officer or representative or in any other capacity while serving as a director, officer or representative, shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment to the fullest extent permitted by law, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than said law permitted the Corporation to provide prior to such amendment), against all expenses, liability and loss (including attorneys' fees, judgments, fines, Employee Retirement Income Security Act of 1974, as amended, excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by him or her in connection therewith and such indemnification shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent and shall inure to the benefit of his or her heirs, executors, and administrators. Such right shall be a contract right and shall include the right to be paid by the Corporation expenses incurred in defending any

such Proceeding in advance of its final disposition; provided, however, if the DGCL requires, the payment of such expenses shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such person to repay all amounts so advanced if it should be determined ultimately by final judicial decision from which there is no further right to appeal that such person is not entitled to be indemnified under this Article IX or otherwise. Unless otherwise required by law, the burden of proving that the Indemnitee is not entitled to be indemnified or to such advancement of expenses under this Article IX shall be on the Corporation. The Corporation may, by action of the Board, provide indemnification to employees and/or agents with the same scope and effect as the foregoing indemnification of directors and officers. Notwithstanding anything to the contrary in this Article IX and except as provided in paragraph (C) of this Article IX with respect to Proceedings to enforce rights to indemnification, the Corporation shall not be required to indemnify any Indemnitee against expenses incurred in connection with a Proceeding (or part thereof) initiated by such Indemnitee unless the initiation of the Proceeding (or part thereof) was approved by the Board of Directors.

C. If a claim under this Article IX is not paid in full by the Corporation within thirty days after a written claim has been received by the Corporation, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and if successful, in whole or in part, the Indemnitee shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any Proceeding in advance of its final disposition where the undertaking, if any is required, has been tendered to the Corporation) that the Indemnitee has not met the standards of conduct which make it permissible under the DGCL for the Corporation to indemnify the Indemnitee for the amount claimed, but the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the Indemnitee is proper in the circumstances because he has met the applicable standard of conduct set forth in the DGCL, nor an actual determination by the Corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the Indemnitee had not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the Indemnitee had not met the applicable standard of conduct.

D. Any amendment, alteration or repeal of this Article IX that adversely affects any right of an Indemnitee or his or her successors shall be prospective only and shall not limit or eliminate any such right with respect to any proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment or repeal.

E. The rights conferred by this Article IX shall not be exclusive of any other right which such Indemnitees may have or hereafter acquire under any statute, provision, bylaw, agreement, vote of stockholders or disinterested directors or otherwise.

F. The Corporation may maintain insurance, at its expense, to protect itself and any director, officer, or representative against any such expense, liability or loss, whether or not the Corporation would have the power to indemnify him against such expense, liability or loss under the DGCL.

**ARTICLE X
DEFINITIONS**

For purposes of this Third Amended and Restated Certificate of Incorporation:

- A. "affiliate" has the same meaning given to that term under Rule 12b-2 promulgated under the Exchange Act.
- B. "Exchange Act" means the Securities Exchange Act of 1934, as amended.
- C. "Wanda" means Dalian Wanda Group Co., Ltd, company organized under the laws of the People's Republic of China.

**ARTICLE XI
AMENDMENT**

A. The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Fourth Amended and Restated Certificate of Incorporation in the manner now or hereafter prescribed by the DGCL, and all rights conferred upon stockholders herein are granted subject to this reservation.

B. In furtherance and not in limitation of the power conferred upon the Board of Directors by law, the Board of Directors shall have the power without the assent or vote of the stockholders to adopt, amend, alter or repeal the bylaws of the Corporation.

IN WITNESS WHEREOF, the undersigned has caused this Fourth Amended and Restated Certificate of Incorporation to be executed by a duly authorized officer of the Corporation, this 10th day of December, 2025.
AMC ENTERTAINMENT HOLDINGS, INC.

By: /s/ Edwin F. Gladbach -

Printed Name: Edwin F. Gladbach

Title: Senior Vice President, General Counsel and Secretary

CERTIFICATIONS

I, Adam M. Aron, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AMC Entertainment Holdings, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 23, 2026

/s/ ADAM M. ARON

Adam M. Aron

Chairman of the Board, Chief Executive Officer and President

CERTIFICATIONS

I, Sean D. Goodman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of AMC Entertainment Holdings, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: July 23, 2026

/s/ SEAN D. GOODMAN

Sean D. Goodman

Executive Vice President, International Operations, Chief Financial Officer and Treasurer

CERTIFICATION OF PERIODIC REPORT

The undersigned Chairman of the Board, Chief Executive Officer and President and Executive Vice President, International Operations, Chief Financial Officer and Treasurer of AMC Entertainment Holdings, Inc. (the “Company”), each hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

- (1) the Quarterly Report on Form 10-Q of the Company for the quarter ended June 30, 2026 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: July 23, 2026

/s/ ADAM M. ARON

Adam M. Aron

Chairman of the Board, Chief Executive Officer and President

/s/ SEAN D. GOODMAN

Sean D. Goodman

Executive Vice President, International Operations, Chief Financial Officer and Treasurer
